2018 Annual Meeting AAN Extra — Saturday, Apr 21 by American Academy of Neurology

THE ANNUAL MEETING NEWS DAILY

Saturday, April 21, 2018

TRANSLATIONAL RESEARCH HIGHLIGHTED IN TODAY’S PLENARY SESSION Kicking off the seven premier plenary sessions is today’s Hot Topics Plenary Session in South Exhibit Hall K from 4:15 p.m. to 5:30 p.m. Eric Klawiter, MD, moderates the session, which features translational research related to clinical issues of importance, with researchers providing summaries of their findings and describing the clinical importance of the results. This plenary session will feature audience response technology to create Klawiter an interactive attendee experience. Continued on page 16 u

Participate in Today’s AAN Business Meeting

More Than 2,200 Los Angeles Area Residents Seek Latest Information and Fun at Friday’s Brain Health Fair The AAN’s annual family-friendly event designed to connect members of the public with local and international neurologist experts proved a big hit with Los Angeles area patients, caregivers, families, and students. More than 2,200 people flocked to the Los Angeles

AAN members are encouraged to attend the AAN Business Meeting, taking place this afternoon from 3:00 p.m. to 4:00 p.m. in 404AB in the Los Angeles Convention Center. Academy leadership will review the Academy’s strategic priorities, recent accomplishments on behalf of members, and the Academy’s current fiscal performance. 

INSIDE

Neurology History Comes Alive with AAN 70th Anniversary Exhibit and More

Hall Opens 17 Exhibit Tomorrow—Don’t Miss These Highlights Week’s “Best of” 20 This Scientific Platform Sessions Highlight Top-scoring Abstracts AAN Award Recipients 35 2018 Announced

AAN President Ralph L. Sacco, MD, MS, FAHA, FAAN,

Continued on page 10 u spoke to attendees at the 2017 business meeting in Boston.

In Multiple Sclerosis, when it comes to Brain Preservation

Grey Matters, Too JOIN US AT

Booth 932

Saturday, April 21 Cover Translational Research Highlighted in Today’s Plenary Session

3 4 6 9 9

More Than 2,200 Los Angeles Area Residents Seek Latest Information and Fun at Friday’s Brain Health Fair Participate in Today’s AAN Business Meeting Daily Reminders Today’s Experiential Learning Area Highlights Neurology History Comes Alive with AAN 70th Anniversary Exhibit and More Resiliency Is Focus of Leadership University Course Get Your Career in Gear During the Annual Meeting Online Job Fair

16 Don’t Forget to Use the Conferences App to Get the Most out of Your Week

17 Exhibit Hall Opens Tomorrow—Don’t Miss These Highlights

20 This Week’s “Best of” Scientific

The Vision of the AAN is to be indispensable to our members.

21 Get Connected to Synapse at the

The Mission of the AAN is to promote the highest quality patient-centered neurologic care and enhance member career satisfaction.

Platform Sessions Highlight Topscoring Abstracts Member Experience: Personalize Your Journey Experiential Learning Area

22 Tweets of the Day 23 If You’re New to the Annual Meeting, These Opportunities Are for You!

27 Quotable Quotes 28 Who Will Win This Year’s Coveted

Neurobowl Trophy? Find Out Tonight!

28 Today’s Boxed Lunch Menu 30 Build, Expand Your Leadership Potential—All Week Long

34 Medical Students and Residents:

Help Build Your Careers in Research

35 2018 AAN Award Recipients Announced

39 Congratulations 2018

Neuro Film Festival Winners!

Contact Information: American Academy of Neurology 201 Chicago Avenue Minneapolis, MN 55415 USA Phone: (800) 879-1960 (Toll Free) or (612) 928-6100 (International) Fax: (612) 454-2744 Email: memberservices@aan.com Website: AAN.com AAN Executive Director/CEO: Catherine M. Rydell, CAE

Managing Editor: Angela Babb, CAE Editor: Tim Streeter Writers: Ryan Knoke, Sarah Parsons Designer: Jim Hopwood Photography: Will Evans Printing: Lithographix, Inc. Email: aannews@aan.com AANextra is published by the American Academy of Neurology. The American Academy of Neurology’s registered trademarks and service marks are registered in the United States and various other countries around the world. “American Brain Foundation” is a registered service mark of the American Brain Foundation and is registered in the United States.

18 Look for Complimentary Shuttle Service at Select Hotels

Daily Reminders Education Program Syllabi and Slides Available Online Only Education Program syllabi and slides are available online only at AAN.com/view/ syllabi or through the AAN Conferences Mobile App at AAN.com/view/ MobileApp.

Log into the New AAN.com for Chance to Win! Log in on the Academy’s freshly redesigned AAN.com and you could win an Apple HomePod or Alexa Echo Plus. The drawing is open to any AAN member who logs in to AAN.com from Sunday to Thursday or stops by the

AAN.com booth. The drawing will be held at noon on Thursday, and you must be present at the AAN.com booth to win.

May 7 Is Deadline to Submit Online Evaluations for Annual Meeting CME Complete your evaluations to get your CME hours by using the AAN Conferences Mobile App at AAN.com/ view/MobileApp or by visiting AAN.com/ view/CME. CME requests may be made until Monday, May 7, 2018. 

The American Academy of Neurology sincerely thanks Lithographix, Inc. for its outstanding service, steadfast professionalism, and high quality standards, as well as its generous donation of the 2018 Brain Health Fair program guide.

Today’s Experiential Learning Area Highlights HeadTalks

Live Well: Taking Care of Your Patients Starts with Taking Care of You

Rural Neurology 2:00 p.m.–3:00 p.m. The demand for neurologists throughout the country is increasing—and many of the locations with the highest need are in rural areas. Join Dario Beltran MD, FAAN, and Michael Stitzer, MD, in a discussion about the challenges and rewards of such a practice.

Complimentary Chair Massages Sunday–Friday, 12:00 p.m.–4:00 p.m.

Yoga (all-levels Vinyasa) Sunday–Friday, 7:00 a.m.–7:45 a.m.

Women in Neurology: Crafting Your Leadership Career: Lessons from Leaders 3:15 p.m.–4:15 p.m. The following renowned women in neurology will share their leadership journeys and discuss their challenges and successes throughout their careers: Allison Brashear, MD, MBA, FAAN; Cynthia Comella, MD, FAAN; Helena Chui, MD; Merit Cudkowicz, MD, MSC; Mona Bahouth, MD; Barbara Vickrey, MD, MPH, FAAN.

Brashear

Saturday, April 21, 2018 • AANextra

Comella

Maximize Your Value and Advocacy to Action How Can the Axon Registry Improve My Practice? 9:30 a.m.–10:00 a.m. Have you been curious about how the Axon Registry ® can help you improve your practice and enhance your quality improvement activities? Axon expert Sarah Benish, MD, FAAN, will share her knowledge about and experience in using the Axon Registry to make her practice more efficient.

Cudkowicz

Navigating Your Career Interviewing Skills: Medical Students and Residents 1:15 p.m.–2:00 p.m. Residency and fellowship interviews are a critical step in the career of trainees. Join Ezgi Tiryaki, MD, FAAN, as she shows you how to make the most of the interview experience.

Research Corner: Moving Neurology Forward Young Investigator Day 7:30 a.m.–2:10 p.m. Support your budding career in research with a variety of presentations taking place throughout the day designed specifically for preand early-career researchers. Kick off the day’s lineup of critical advice with “Are You My Mentor? How to Select a Good Mentor for Your Research Career,” led by Deborah Hall, MD, PhD, FAAN, and beginning at 7:30 a.m. Other highlights include:

The Member Experience: Personalize Your Journey It’s All About You. All Week Long. We love our members. And we’re ready to show you all the steps we’ve taken to help you connect, engage, and personalize your member experience to make it all your own. 

10:00 a.m.–10:50 a.m.: Investigator Panel: How I Launched My Career with NIH Funding, AAN Research Program Funding, and/or Government Funding 11:30 a.m.–12:00 p.m.: Office Hours: Research Careers in Industry 12:20 p.m.–12:50 p.m.: How to Find Training: The Best Clinical Research and Methodology Training Options

Saturday, April 21, 2018 • AANextra

Neurology History Comes Alive with AAN 70th Anniversary Exhibit and More As the AAN celebrates its 70 th anniversary, Annual Meeting attendees are invited to learn more about the Academy’s history and its founders in a unique exhibit located outside of South Exhibit Hall K of the South Hall area, near the entrance to the Plenary Sessions. A 40 x 8-foot panel recreates the History Wall displayed at the AAN’s headquarters in Minneapolis—a grand collage of images, events, and people associated with the success of the world’s largest association of neurologists. A series of video interviews with past Academy presidents can be viewed, and attendees can take selfies in front of a 10 x 8-foot photo of founder A.B. Baker. Also on display are four cases containing neurology memorabilia. Two cases feature autographed books written by the “Four Horsemen” central to the creation of the AAN—Baker and his colleagues Francis M. Forster, Adolph L. Sahs, and Russell N. DeJong—as well as the 1949 letter notifying Joseph A. Resch that he was accepted as a junior member of the Academy. Resch was the neurology resident at the University of Minnesota who complained to Baker— his department chair—that he had no place to continue his training after he entered the work force and wouldn’t be eligible to join the American Neurology Association. That conversation set in motion 70 years of history we celebrate in 2018. The other display cases hold a black leather medical bag and tools owned by Forster that was given to the Academy by his family after his death in 2006. Stop by to look over these tools and compare them to what you use today when examining patients. You are also invited to guess what some of the tools were used for. The AAN’s History and Archives Committee Chair Douglas J. Lanska, MD, FAAN, will note the anniversary during Sunday’s Presidential Plenary Session, held from 9:15 a.m. to noon in South Exhibit Hall K across from the History exhibit.

Saturday, April 21, 2018 • AANextra

Other opportunities to learn more about the history of the AAN and neurology include: Hall of Presidents: Using Past Experience to Solve Future Problems Sunday, 1:30 p.m.−2:30 p.m. Moderated by AAN President Ralph L. Sacco, MD, MS, FAHA, FAAN. Former presidents scheduled to appear include current Past President Terrence L. Cascino, MD, FAAN; Stanley Fahn MD, FAAN; Robert C. Griggs, MD, FAAN; Francis I. Kittredge, MD, FAAN; Timothy A. Pedley, MD, FAAN; Sandra F. Olson, MD, FAAN; Roger N. Rosenberg, MD, FAAN; Stephen M. Sergay, MB BCh, FAAN; and Thomas R. Swift, MD, FAAN. Experiential Learning Area (HeadTalk Stage) History Section Meeting/ Tyler Award Presentation Monday, 12:00 p.m.–1:00 p.m. Why Study the History of Neurology?—A Panel Discussion Featuring the Lawrence C. McHenry Award and Roland P. Mackay Medical Student Essay Award Winners Monday, 2:20 p.m.–2:50 p.m. Christopher J. Boes, MD, FAAN Experiential Learning Area (Research Corner) Neurology of the 1970s Monday, 5:15 p.m.–6:15 p.m. Martin A. Samuels, MD, MACP, FAAN; Thomas R. Swift, MD, FAAN; Austin J. Sumner, MD, FAAN; Sandra F. Olson, MD, FAAN Experiential Learning Area (HeadTalk Stage)

Oral Archive Interview of J.C. Dyck, Sr., MD, FAAN, by Christopher J. Boes, MD, FAAN Tuesday, 2:00 p.m.–3:00 p.m. Oral Archive Interview of former AAN President Sandra F. Olson, MD, FAAN, by Stephen G. Reich, MD, FAAN Tuesday, 4:30 p.m.–5:30 p.m. Neurology History: Weaving Past with Present Thursday, 4:30 p.m.–5:30 p.m. Christopher Goetz, MD, FAAN Experiential Learning Area (HeadTalk Stage) Historical Perspective on Treating Epilepsy Friday, 4:00 p.m.–4:30 p.m. Experiential Learning Area (Research Corner)

Education Courses C150 Where is the Lesion? A History of Neurological Investigations Part I Wednesday, 1:00 p.m.–3:00 p.m. Stefano Sandrone, PhD C165 Where is the Lesion? A History of Neurological Investigation Part II Wednesday, 3:30 p.m.–5:30 p.m. Stefano Sandrone, PhD

Science Programs

S39 History of Neurology Thursday, 1:00 p.m.–2:15 p.m. 

THE FIRST FDA-APPROVED TREATMENT INDICATED FOR ADULTS WITH TARDIVE DYSKINESIA (TD)1

ONE CAPSULE, ONCE DAILY1 Convenient, once-daily dosing without complex titration1

Not actual size

• INGREZZA 80 mg provided rapid and significant reductions in TD severity by 6 weeks1,2 —with continued reductions in TD severity through 48 weeks1,3 • Generally well tolerated in clinical trials across a broad range of TD patients1,2 • Selectively inhibits VMAT2, with no appreciable binding affinity for dopaminergic (including D2) or serotonergic receptors1

VMAT2, vesicular monoamine transporter 2.

Not an actual patient

I S I T T D O R A C U T E E P S ? | TA K E T H E T D C H A L L E N G E AT B O O T H # 1 0 2 2 EPS, extrapyramidal symptoms.

W W W. I N G R E Z Z A H C P. C O M

Important Information INDICATION & USAGE

INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION WARNINGS & PRECAUTIONS Somnolence INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

ADVERSE REACTIONS

The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Please see the adjacent page for brief summary of Prescribing Information and visit www.INGREZZAHCP.com for full Prescribing Information. REFERENCES: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc; 2017. 2. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484. 3. Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-Year KINECT 3 extension study. J Clin Psychiatry. 2017;78(9):1344-1350.

for oral use

Brief Summary: for full Prescribing Information and Patient Information, refer to package insert. INDICATIONS AND USAGE

INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

WARNINGS AND PRECAUTIONS

Somnolence INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA. QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA concentrations may be higher and QT prolongation clinically significant. For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. For patients taking a strong CYP3A4 inhibitor, reduce the dose of INGREZZA to 40 mg once daily. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Endocrine Disorders: blood glucose increased General Disorders: weight increased Infectious Disorders: respiratory infections Neurologic Disorders: drooling, dyskinesia, extrapyramidal symptoms (non-akathisia) Psychiatric Disorders: anxiety, insomnia During controlled trials, there was a dose-related increase in prolactin. Additionally, there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis.

DRUG INTERACTIONS

Drugs Having Clinically Important Interactions with INGREZZA Table 2: Clinically Significant Drug Interactions with INGREZZA Monoamine Oxidase Inhibitors (MAOIs) Clinical Implication:

Prevention or Management: Examples: isocarboxazid, phenelzine, selegiline Strong CYP3A4 Inhibitors Clinical Implication:

ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling: • Somnolence • QT Prolongation Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Prevention or Management: Examples: Strong CYP2D6 Inhibitors

The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% African-American, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry. Adverse Reactions Leading to Discontinuation of Treatment A total of 3% of INGREZZA treated patients and 2% of placebo-treated patients discontinued because of adverse reactions. Common Adverse Reactions Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of ≥2% and greater than placebo are presented in Table 1. Table 1: Adverse Reactions in 3 Placebo-Controlled Studies of 6-week Treatment Duration Reported at ≥2% and >Placebo INGREZZA (n=262) (%)

Placebo (n=183) (%)

Concomitant use of INGREZZA with strong CYP2D6 inhibitors may increase the exposure (Cmax and AUC) to valbenazine’s active metabolite compared with the use of INGREZZA alone. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions.

Prevention or Management:

Consider reducing INGREZZA dose based on tolerability when INGREZZA is coadministered with a strong CYP2D6 inhibitor.

Examples:

paroxetine, fluoxetine, quinidine

10.9%

4.2%

Anticholinergic effects (dry mouth, constipation, disturbance in attention, vision blurred, urinary retention)

5.4%

4.9%

Balance disorders/fall (fall, gait disturbance, dizziness, balance disorder)

4.1%

2.2%

Headache Akathisia (akathisia, restlessness)

3.4% 2.7%

2.7% 0.5%

Vomiting Nausea Musculoskeletal Disorders

2.6% 2.3%

0.6% 2.1%

Arthralgia

2.3%

0.5%

Strong CYP3A4 Inducers Clinical Implication:

Prevention or Management: Examples: Digoxin

General Disorders Somnolence (somnolence, fatigue, sedation) Nervous System Disorders 1

Gastrointestinal Disorders

Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency.

Other Adverse Reactions Observed During the Premarketing Evaluation of INGREZZA Other adverse reactions of ≥1% incidence and greater than placebo are shown below. The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo.

Concomitant use of INGREZZA with strong CYP3A4 inhibitors increased the exposure (Cmax and AUC) to valbenazine and its active metabolite compared with the use of INGREZZA alone. Increased exposure of valbenazine and its active metabolite may increase the risk of exposure-related adverse reactions. Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP3A4 inhibitor. itraconazole, ketoconazole, clarithromycin

Clinical Implication:

Variable and Fixed Dose Placebo-Controlled Trial Experience

Adverse Reaction1

Concomitant use of INGREZZA with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA. Avoid concomitant use of INGREZZA with MAOIs.

Concomitant use of INGREZZA with a strong CYP3A4 inducer decreased the exposure of valbenazine and its active metabolite compared to the use of INGREZZA alone. Reduced exposure of valbenazine and its active metabolite may reduce efficacy. Concomitant use of strong CYP3A4 inducers with INGREZZA is not recommended. rifampin, carbamazepine, phenytoin, St. John’s wort1

Clinical Implication:

Concomitant use of INGREZZA with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp).

Prevention or Management:

Digoxin concentrations should be monitored when co-administering INGREZZA with digoxin. Increased digoxin exposure may increase the risk of exposure related adverse reactions. Dosage adjustment of digoxin may be necessary.

The induction potency of St. John’s wort may vary widely based on preparation.

Drugs Having No Clinically Important Interactions with INGREZZA Dosage adjustment for INGREZZA is not necessary when used in combination with substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5 based on in vitro study results.

OVERDOSAGE

Human Experience The pre-marketing clinical trials involving INGREZZA in approximately 850 subjects do not provide information regarding symptoms with overdose. Management of Overdosage No specific antidotes for INGREZZA are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org). For further information on INGREZZA, call 84-INGREZZA (844-647-3992). Distributed by: Neurocrine Biosciences, Inc. San Diego, CA 92130 INGREZZA is a trademark of Neurocrine Biosciences, Inc. CP-VBZ-US-0203v2 09/17

Resiliency Is Focus of Leadership University Course The issue of burnout is prevalent in medicine and neurology, with personal, professional, and organizational implications. We all have the potential to be leaders of change in our work units and organizations to promote wellness and resilience. Those efforts can fuel policy changes at a state and national level. In Sunday’s fourhour, interactive course “Being a Resilient Leader: How Do You Lead the Change,” directors Heidi B. Schwarz, MD, FAAN, and Jennifer Molano Rose Molano, MD, FAAN, along with a panel of current leaders, will share the current knowledge and creative approaches to addressing factors contributing to burnout in the work unit and organizational structure to increase engagement and resilience for not only the participants but other team members; discuss challenges in promoting resiliency

at one’s local organization, clinic, or institution; and identify strategies to promote resiliency and professionalism in the culture of one’s local Schwarz organization, clinic, or institution. Using small group and panel discussions, the course will empower neurologists to formulate their own plans for promoting resiliency and becoming leaders in their own communities. The session will take place from 1:00 p.m. to 5:00 p.m. in 406AB. No advance registration is needed for the course, which is free and included with your Annual Meeting registration; however, seating is limited. Use the conference mobile app at AAN.com/view/mobileapp to add to the program to your itinerary. 

Get Your Career in Gear During the Annual Meeting Online Job Fair The Annual Meeting is the perfect time and place to start laying the groundwork—or continue your process—to explore job opportunities and network with colleagues and key contacts. Visit the Neurology Career Center Booth in the West Lobby or the Exhibit Hall of the convention center to learn more about important resources to help with your job search.

Win $500 Visit the Neurology Career Center online at Careers.AAN.com and you could win $500! Simply create or update your Job Seeker profile by April 27 to be eligible to win.

Free Gifts Visit the Neurology Career Center and pick up free gifts, including t-shirts, pens, and more—while quantities last!

Convention Center West Lobby Saturday, April 21–Friday, April 27, 7:00 a.m.–6:00 p.m. Daily

Exhibit Hall Booth Sunday, April 22–Tuesday, April 24, 11:30 a.m.–4:00 p.m. Wednesday, April 25, 11:30 a.m.–3:00 p.m. 

Saturday, April 21, 2018 • AANextra

More Than 2,200 Los Angeles Area Residents Seek Latest Information and Fun at Friday’s Brain Health Fair Continued from cover

Convention Center yesterday eager to learn about the latest research advances and new treatments for brain diseases including multiple sclerosis, memory disorders, epilepsy, stroke, movement disorders, neuromuscular disease, headache, concussion, neurogenetic conditions, neurooncology, pediatric neurology, and others. While there, attendees were met with countless fun, interactive, and informative opportunities to learn about the wonders of the brain. Some of the day’s biggest hits gave curious participants a chance to: Journey through a giant, inflatable brain Have a virtual reality experience See their own brains through imaging View human brains Meet trained local service dogs and see them in action Pick up a free bike helmet

Saturday, April 21, 2018 • AANextra

Ask questions at the “Ask a Neurologist” booths Test their brains with optical illusions Tour the UCLA Mobile Stroke Unit Visit Neuroscience Is…™ Cool and experience a neuro exam Get moving to measure their own gait and see how gait changes in different neurologic disorders Get free resources and attend Q&A presentations en Español Learn about home modifications, resources, and technology for patients The 2018 Brain Health Fair Platinum Sponsors were Amgen & Novartis Corporation and Greenwich Biosciences; Gold Sponsors were Levy LA Convention Center and Sanofi Genzyme.; and Silver Sponsors were EMD Serono, Freeman, Mitsubishi Tanabe Pharma America, Supernus Pharmaceuticals Inc.; Sunovion Pharmaceuticals Inc.; PSAV Presentation Services. 

Saturday, April 21, 2018 • AANextra

For patients with epilepsy 12 years of age and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures and adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures

RETHINK CO N V U L S I V E S E I Z U R E CO NTRO L AT B O OTH 17 15

HELP QUIET THE NOISE OF CONVULSIVE SEIZURES

Prescribed for

100,000 PATIENTS1*†

Approved in

Available in

COUNTRIES1†

FORMULATIONS2

TO LEARN MORE, VISIT FYCOMPA .COM/HCP Please see Important Safety Information, including a Boxed WARNING for Serious Psychiatric and Behavioral Reactions, on adjacent page. Please see Brief Summary of Prescribing Information on following pages.

* Worldwide figure for FYCOMPA® from 2012 through July 2017. Nearly 20,000 patients prescribed FYCOMPA in the United States. †Across different indications.

IMPORTANT SAFETY INFORMATION WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS • Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA® • These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression • Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA • Closely monitor patients particularly during the titration period and at higher doses • FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening

SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS

SOMNOLENCE AND FATIGUE FYCOMPA caused dose-dependent increases in somnolence and fatigue-related events. Somnolence was reported in 16% and 18% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 7% of placebo-treated patients. Fatigue-related events were reported in 12% and 15% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 5% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase. These adverse reactions were also observed in the PGTC seizure clinical trial. Patients should be advised against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of FYCOMPA is known.

FALLS Falls were reported in 5% and 10% of patients in the partial-onset seizure clinical trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 3% of placebo-treated patients.

DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS)

In the partial-onset seizures clinical trials, hostility- and aggression-related adverse reactions occurred in 12% and 20% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. These effects in FYCOMPA-treated patients led to dose reduction, interruption, and discontinuation more frequently than placebo-treated patients. Homicidal ideation and/or threat have also been reported postmarketing in patients treated with FYCOMPA. The combination of alcohol and FYCOMPA significantly worsened mood and increased anger. Patients taking FYCOMPA should avoid the use of alcohol. Patients, their caregivers, and families should be informed that FYCOMPA may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least one month after the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases. Similar serious psychiatric and behavioral events were observed in the primary generalized tonic-clonic (PGTC) seizure clinical trial.

DRESS, also known as multiorgan hypersensitivity, has been reported in patients taking AEDs, including FYCOMPA. DRESS may be fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement. If signs or symptoms are present, immediately evaluate the patient and discontinue FYCOMPA if an alternative etiology for signs or symptoms cannot be established.

SUICIDAL BEHAVIOR AND IDEATION

FYCOMPA may decrease the efficacy of contraceptives containing levonorgestrel. Plasma levels of FYCOMPA were decreased when administered with moderate and strong CYP3A4 inducers, including, carbamazepine, phenytoin, or oxcarbazepine. Multiple dosing of FYCOMPA 12 mg per day enhanced the effects of alcohol on vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when FYCOMPA is used in combination with other CNS depressants.

Antiepileptic drugs (AEDs), including FYCOMPA, increase the risk of suicidal thoughts or behavior in patients. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, their caregivers, and families should be informed of the risk and advised to monitor and immediately report the emergence or worsening of depression, suicidal thoughts or behavior, thoughts about self-harm and/or any unusual changes in mood or behavior. Should suicidal thoughts and behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

DIZZINESS AND GAIT DISTURBANCE FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination. Dizziness and vertigo were reported in 35% and 47% of patients in the partial-onset seizure trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 10% of placebo-treated patients. Gait disturbance related events were reported in 12% and 16% of patients in the partial-onset seizure clinical trials randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 2% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase. These adverse reactions were also observed in the PGTC seizure clinical trial.

WITHDRAWAL OF AEDs A gradual withdrawal is generally recommended with AEDs to minimize the potential of increased seizure frequency, but if withdrawal is a response to adverse events, prompt withdrawal can be considered.

MOST COMMON ADVERSE REACTIONS The most common adverse reactions in patients receiving FYCOMPA (≥5% and ≥1% higher than placebo) include dizziness, somnolence, fatigue, irritability, falls, nausea, weight gain, vertigo, ataxia, headache, vomiting, contusion, abdominal pain, and anxiety.

DRUG INTERACTIONS

PREGNANCY AND LACTATION Physicians are advised to recommend that pregnant patients taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. Caution should be exercised when FYCOMPA is administered to pregnant or nursing women as there are no adequate data on the developmental risk associated with use in pregnant women, and no data on the presence of perampanel in human milk, the effects on the breastfed child, or the effects of the drug on milk production.

HEPATIC AND RENAL IMPAIRMENT Use in patients with severe hepatic or severe renal impairment is not recommended. Dosage adjustments are recommended in patients with mild or moderate hepatic impairment. Use with caution in patients with moderate renal impairment.

DRUG ABUSE AND DEPENDENCE FYCOMPA is a Schedule III controlled substance and has the potential to be abused and lead to drug dependence.

REFERENCES: 1. Data on file. Eisai Inc. Woodcliff Lake, NJ. 2. FYCOMPA US Prescribing Information. Woodcliff Lake, NJ: Eisai Inc.

Please see Brief Summary of Prescribing Information on following pages. FYCOMPA® is a registered trademark of Eisai R&D Management Co., Ltd., licensed to Eisai Inc. ©2018 Eisai Inc. FYCO-US2026 March 2018

FYCOMPA® (perampanel) tablets, for oral use, CIII FYCOMPA® (perampanel) oral suspension, CIII Initial U.S. Approval: 2012 Brief Summary of Full Prescribing Information dated July 2017 WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS • Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA. • These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression. • Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA. • Closely monitor patients particularly during the titration period and at higher doses • FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening. WARNINGS AND PRECAUTIONS Serious Psychiatric and Behavioral Reactions In the controlled partial-onset seizure clinical trials, hostilityand aggression-related adverse reactions occurred in 12% and 20% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. FYCOMPA-treated patients experienced more hostility- and aggression-related adverse reactions that were serious, severe, and led to dose reduction, interruption, and discontinuation more frequently than placebo-treated patients. In general, in placebo-controlled partial-onset seizure clinical trials, neuropsychiatric events were reported more frequently in patients being treated with FYCOMPA than in patients taking placebo. These events included irritability, aggression, anger, and anxiety, which occurred in 2% or greater of FYCOMPA-treated patients and twice as frequently as in placebo-treated patients. Other symptoms that occurred with FYCOMPA and were more common than with placebo included belligerence, affect lability, agitation, and physical assault. Some of these events were reported as serious and life-threatening. Homicidal ideation and/or threat were exhibited in 0.1% of 4,368 FYCOMPA-treated patients in controlled and open label trials, including non-epilepsy trials. Homicidal ideation and/or threat have also been reported postmarketing in patients treated with FYCOMPA. In the partial-onset seizure clinical trials, these events occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression. Some patients experienced worsening of their pre-existing psychiatric conditions. Patients with active psychotic disorders and unstable recurrent affective disorders were excluded from the clinical trials. The combination of alcohol and FYCOMPA significantly worsened mood and increased anger. Patients taking FYCOMPA should avoid the use of alcohol. Similar serious psychiatric and behavioral events were observed in the primary generalized tonic-clonic seizure clinical trial. In healthy volunteers taking FYCOMPA, observed psychiatric events included paranoia, euphoric mood, agitation, anger, mental status changes, and disorientation/confusional state. In the non-epilepsy trials, psychiatric events that occurred in perampanel-treated patients more often than placebo-treated patients included disorientation, delusion, and paranoia. Patients, their caregivers, and families should be informed that FYCOMPA may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least 1 month after the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases. Dose of FYCOMPA should be reduced if these symptoms occur. Permanently discontinue FYCOMPA for persistent severe or worsening psychiatric symptoms or behaviors and refer for psychiatric evaluation. Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including FYCOMPA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 1 shows absolute and relative risk by indication for all evaluated AEDs. Table 1. Risk by indication for antiepileptic drugs in the pooled analysis Indication

Placebo Patients with Events per 1000 Patients

Drug Patients with Events per 1000 Patients

Epilepsy Psychiatric Other Total

1.0 5.7 1.0 2.4

3.4 8.5 1.8 4.3

Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients 3.5 1.5 1.9 1.8

Risk Difference: Additional Drug Patients with Events per 1000 Patients 2.4 2.9 0.9 1.9

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Neurologic Effects Dizziness and Gait Disturbance FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination. In the controlled partial-onset seizure clinical trials, dizziness and vertigo were reported in 35% and 47% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 10% of placebo-treated patients. The gait disturbance related events (including ataxia, gait disturbance, balance disorder, and abnormal coordination) were reported in 12% and 16% of patients randomized to

receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 2% of placebo-treated patients. Elderly patients had an increased risk of these adverse reactions compared to younger adults and pediatric patients. These adverse reactions occurred mostly during the titration phase and led to discontinuation in 3% of FYCOMPA-treated patients compared to 1% of placebo-treated patients. These adverse reactions were also observed in the primary generalized tonic-clonic seizure clinical trial. Somnolence and Fatigue FYCOMPA caused dose-dependent increases in somnolence and fatigue-related events (including fatigue, asthenia, and lethargy). In the controlled partial-onset seizure clinical trials, 16% and 18% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, reported somnolence compared to 7% of placebo patients. In the controlled partial-onset seizure clinical trials, 12% and 15% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, reported fatigue-related events compared to 5% of placebo patients. Somnolence or fatigue-related events led to discontinuation in 2% of FYCOMPA-treated patients and 0.5% of placebo-treated patients. Elderly patients had an increased risk of these adverse reactions compared to younger adults and pediatric patients. In the controlled partial-onset seizure clinical trials, these adverse reactions occurred mostly during the titration phase. These adverse reactions were also observed in the primary generalized tonic-clonic seizure clinical trial. Risk Amelioration Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of FYCOMPA is known. Falls An increased risk of falls, in some cases leading to serious injuries including head injuries and bone fracture, occurred in patients being treated with FYCOMPA (with and without concurrent seizures). In the controlled partial-onset seizure clinical trials, falls were reported in 5% and 10% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg per day, respectively, compared to 3% of placebo-treated patients. Falls were reported as serious and led to discontinuation more frequently in FYCOMPA-treated patients than placebo-treated patients. Elderly patients had an increased risk of falls compared to younger adults and pediatric patients. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including FYCOMPA. DRESS may be fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. FYCOMPA should be discontinued if an alternative etiology for the signs or symptoms cannot be established. Withdrawal of Antiepileptic Drugs There is the potential of increased seizure frequency in patients with seizure disorders when antiepileptic drugs are withdrawn abruptly. FYCOMPA has a half-life of approximately 105 hours so that even after abrupt cessation, blood levels fall gradually. In epilepsy clinical trials FYCOMPA was withdrawn without down-titration. Although a small number of patients exhibited seizures following discontinuation, the data were not sufficient to allow any recommendations regarding appropriate withdrawal regimens. A gradual withdrawal is generally recommended with antiepileptic drugs, but if withdrawal is a response to adverse events, prompt withdrawal can be considered. ADVERSE REACTIONS Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Partial-Onset Seizures A total of 1,038 patients receiving FYCOMPA (2, 4, 8, or 12 mg once daily) constituted the safety population in the pooled analysis of the placebo-controlled trials (Studies 1, 2, and 3) in patients with partial-onset seizures. Approximately 51% of patients were female, and the mean age was 35 years. Adverse Reactions Leading to Discontinuation In controlled clinical trials (Studies 1, 2, and 3), the rate of discontinuation as a result of an adverse reaction was 3%, 8%, and 19% in patients randomized to receive FYCOMPA at the recommended doses of 4 mg, 8 mg, and 12 mg per day, respectively, and 5% in patients randomized to receive placebo. The adverse reactions most commonly leading to discontinuation (≥1% in the 8 mg or 12 mg FYCOMPA group and greater than placebo) were dizziness, somnolence, vertigo, aggression, anger, ataxia, blurred vision, irritability, and dysarthria. Most Common Adverse Reactions Table 2 gives the incidence in the controlled clinical trials (Studies 1, 2, and 3) of the adverse reactions that occurred in ≥2% of patients with partial-onset seizures in the FYCOMPA 12 mg dose group and more frequent than placebo (in order of decreasing frequency for the 12 mg dose group). The most common dose-related adverse reactions in patients receiving FYCOMPA at doses of 8 mg or 12 mg (≥4% and occurring at least 1% higher than the placebo group) included dizziness (36%), somnolence (16%), fatigue (10%), irritability (9%), falls (7%), nausea (7%), ataxia (5%), balance disorder (4%), gait disturbance (4%), vertigo (4%), and weight gain (4%). For almost every adverse reaction, rates were higher on 12 mg and more often led to dose reduction or discontinuation. Table 2. Adverse Reactions in Pooled Placebo-Controlled Trials in Patients with Partial-Onset Seizures (Studies 1, 2, and 3) (Reactions ≥ 2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo) Placebo n=442 % Dizziness Somnolence Headache Irritability Fatigue Falls Ataxia Nausea Vertigo Back pain Dysarthria Anxiety Blurred vision Gait disturbance Weight gain Cough Upper respiratory tract infection Vomiting Hypersomnia Anger Aggression Balance disorder Diplopia Head injury Hypoaesthesia Pain in extremity Constipation

9 7 11 3 5 3 0 5 1 2 0 1 1 1 1 3 3 3 0 <1 1 1 1 1 1 1 2

4 mg n=172 % 16 9 11 4 8 2 1 3 4 2 1 2 1 1 4 1 3 2 1 0 1 0 1 1 0 0 2

FYCOMPA 8 mg n=431 % 32 16 11 7 8 5 3 6 3 2 3 3 3 4 4 1 3 3 2 1 2 5 1 1 0 2 2

12 mg n=255 % 43 18 13 12 12 10 8 8 5 5 4 4 4 4 4 4 4 4 3 3 3 3 3 3 3 3 3

Table 2. Adverse Reactions in Pooled Placebo-Controlled Trials in Patients with Partial-Onset Seizures (Studies 1, 2, and 3) (Reactions ≥ 2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo) (cont.) Myalgia Coordination abnormal Euphoric mood Confusional state Hyponatremia Limb injury Mood altered Arthralgia Asthenia Contusion Memory impairment Musculoskeletal pain Oropharyngeal pain Paraesthesia Peripheral edema Skin laceration

2 0 0 <1 <1 <1 <1 1 1 1 1 1 1 1 1 1

1 1 0 1 0 1 1 0 1 0 0 1 2 0 1 0

1 <1 <1 1 0 1 <1 3 2 2 1 1 2 1 1 2

3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

Primary Generalized Tonic-Clonic Seizures A total of 81 patients receiving FYCOMPA 8 mg once daily constituted the safety population in the placebo-controlled trial in patients with primary generalized tonic-clonic seizures (Study 4). Approximately 57% of patients were female, and the mean age was 27 years. In the controlled primary generalized tonic-clonic seizure clinical trial (Study 4), the adverse reaction profile was similar to that noted for the controlled partial-onset seizure clinical trials (Studies 1, 2, and 3). Table 3 gives the incidence of adverse reactions in patients receiving FYCOMPA 8 mg (≥4% and higher than in the placebo group) in Study 4. The most common adverse reactions in patients receiving FYCOMPA (≥10% and greater than placebo) were dizziness (32%), fatigue (15%), headache (12%), somnolence (11%), and irritability (11%). The adverse reactions most commonly leading to discontinuation in patients receiving FYCOMPA 8 mg (≥2% and greater than placebo) were vomiting (2%) and dizziness (2%). Table 3. Adverse Reactions in a Placebo-Controlled Trial in Patients with Primary Generalized Tonic-Clonic Seizures (Study 4) (Reactions ≥ 4% of Patients in FYCOMPA Group and More Frequent than Placebo)

Dizziness Fatigue Headache Somnolence Irritability Vertigo Vomiting Weight gain Contusion Nausea Abdominal pain Anxiety Urinary tract infection Ligament sprain Balance disorder Rash

Placebo n=82 % 6 6 10 4 2 2 2 4 4 5 1 4 1 0 1 1

FYCOMPA 8 mg n=81 % 32 15 12 11 11 9 9 7 6 6 5 5 4 4 4 4

Weight Gain Weight gain has occurred with FYCOMPA. In controlled partial-onset seizure clinical trials, FYCOMPA-treated adults gained an average of 1.1 kg (2.5 lbs) compared to an average of 0.3 kg (0.7 lbs) in placebo-treated adults with a median exposure of 19 weeks. The percentages of adults who gained at least 7% and 15% of their baseline body weight in FYCOMPA-treated patients were 9.1% and 0.9%, respectively, as compared to 4.5% and 0.2% of placebo-treated patients, respectively. Clinical monitoring of weight is recommended. Similar increases in weight were also observed in adult and pediatric patients treated with FYCOMPA in the primary generalized tonic-clonic seizure clinical trial. Elevated triglycerides Increases in triglycerides have occurred with FYCOMPA use. Comparison of Sex and Race No significant sex differences were noted in the incidence of adverse reactions. Although there were few non-Caucasian patients, no differences in the incidence of adverse reactions compared to Caucasian patients were observed. Postmarketing Experience The following adverse reactions have been identified during post approval use of FYCOMPA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Dermatologic: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Psychiatric: Acute psychosis, hallucinations, delusions, paranoia, delirium, confusional state, disorientation, memory impairment. DRUG INTERACTIONS Contraceptives With concomitant use, FYCOMPA at a dose of 12 mg per day reduced levonorgestrel exposure by approximately 40%. Use of FYCOMPA with contraceptives containing levonorgestrel may render them less effective. Additional non-hormonal forms of contraception are recommended. Moderate and Strong CYP3A4 Inducers The concomitant use of known moderate and strong CYP3A4 inducers including carbamazepine, phenytoin, or oxcarbazepine with FYCOMPA decreased the plasma levels of perampanel by approximately 50-67%. The starting doses for FYCOMPA should be increased in the presence of moderate or strong CYP3A4 inducers. When these moderate or strong CYP3A4 inducers are introduced or withdrawn from a patient’s treatment regimen, the patient should be closely monitored for clinical response and tolerability. Dose adjustment of FYCOMPA may be necessary. Alcohol and Other CNS Depressants The concomitant use of FYCOMPA and CNS depressants including alcohol may increase CNS depression. A pharmacodynamic interaction study in healthy subjects found that the effects of FYCOMPA on complex tasks such as driving ability were additive or supra-additive to the impairment effects of alcohol. Multiple dosing of FYCOMPA 12 mg per day also enhanced the effects of alcohol to interfere with vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when FYCOMPA is used in combination with other CNS depressants. Care should be taken when administering FYCOMPA with these agents. Patients should limit activity until they have experience with concomitant use of CNS depressants (e.g., benzodiazepines, narcotics, barbiturates, sedating antihistamines). Advise patients not to drive or operate machinery until they have gained sufficient experience on FYCOMPA to gauge whether it adversely affects these activities. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as FYCOMPA, during pregnancy. Encourage women who are taking FYCOMPA during pregnancy to enroll in the North American Antiepileptic Drug

(NAAED) Pregnancy Registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org. Risk summary There are no adequate data on the developmental risk associated with use in pregnant women. In animal studies, perampanel induced developmental toxicity in pregnant rat and rabbit at clinically relevant doses. In the U.S. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Oral administration of perampanel (1, 3, or 10 mg/kg/day) to pregnant rats throughout organogenesis resulted in an increase in visceral abnormalities (diverticulum of the intestine) at all doses tested; maternal toxicity was observed at the mid and high doses. In a dose-ranging study at higher oral doses (10, 30, or 60 mg/kg/day), embryo lethality and reduced fetal body weight were observed at the mid and high doses tested. The lowest dose tested (1 mg/kg/day) is similar to a human dose of 8 mg per day based on body surface area (mg/m2). Upon oral administration of perampanel (1, 3, or 10 mg/kg per day) to pregnant rabbits throughout organogenesis, embryo lethality was observed at the mid and high doses tested; the no-effect dose for embryo-fetal developmental toxicity in rabbit (1 mg/kg/day) is approximately 2 times a human dose of 8 mg per day based on body surface area (mg/m2). Oral administration of perampanel (1, 3, or 10 mg/kg per day) to rats throughout gestation and lactation resulted in fetal and pup deaths at the mid and high doses (associated with maternal toxicity) and delayed sexual maturation in males and females at the highest dose tested. No effects were observed on measures of neurobehavioral or reproductive function in the offspring. The no-effect dose for pre- and postnatal developmental toxicity in rat (1 mg/kg/day) is similar to a human dose of 8 mg per day based on body surface area (mg/m2). Lactation Risk summary There are no data on the presence of perampanel in human milk, the effects on the breastfed child, or the effects of the drug on milk production. Perampanel and/or its metabolites are excreted in rat milk, and are detected at concentrations higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FYCOMPA and any potential adverse effects on the breastfed child from FYCOMPA or from the underlying maternal condition. Females and Males of Reproductive Potential Contraception Use of FYCOMPA may reduce the efficacy of hormonal contraceptives containing levonorgestrel. Advise women taking FYCOMPA who are using a levonorgestrel-containing contraceptive to use an additional non-hormonal form of contraception while using FYCOMPA and for a month after discontinuation. Pediatric Use The safety and efficacy of FYCOMPA for the treatment of partial-onset seizures in pediatric patients 12 years of age and older was established by three randomized double-blind, placebo-controlled, multicenter studies, which included 72 pediatric patients between 12 and 16 years of age exposed to FYCOMPA. The safety and efficacy of FYCOMPA for the adjunctive therapy of primary generalized tonic-clonic seizures in pediatric patients 12 years of age and older was established in a single randomized double-blind, placebo-controlled, multicenter trial (n=164), which included 11 pediatric patients 12 to 16 years of age exposed to FYCOMPA; an additional 6 patients were treated with FYCOMPA in the open label extension of the study. The safety and effectiveness of FYCOMPA in pediatric patients less than 12 years of age have not been established. Juvenile Animal Data Oral administration of perampanel (1, 3, 3/10/30 mg/kg/day; high dose increased on postnatal days [PND] 28 and 56) to young rats for 12 weeks starting on PND 7 resulted in reduced body weight, reduced growth, neurobehavioral impairment (water maze performance and auditory startle habituation) at the mid and high doses, and delayed sexual maturation at the high doses. CNS signs (reduced activity, incoordination, excessive grooming/scratching), pup death, decreased hindlimb splay, and decreased hindlimb grip strength were observed at all doses. Effects on pup body weight, pup growth, hindlimb splay, impairment in the water maze performance, and auditory startle persisted after dosing was stopped. A no-effect dose for postnatal developmental toxicity was not identified in this study. Oral administration of perampanel (1, 5,5/10 mg/kg/day; high dose increased on PND 56) to juvenile dogs for 33 weeks, starting on PND 42, resulted in CNS signs (incoordination, excessive grooming/licking/scratching, spatial disorientation, and/or ataxic gait) at all doses tested. Geriatric Use Clinical studies of FYCOMPA did not include sufficient numbers of patients aged 65 and over to determine the safety and efficacy of FYCOMPA in the elderly population. Because of increased likelihood for adverse reactions in the elderly, dosing titration should proceed slowly in patients aged 65 years and older. Hepatic Impairment Use of FYCOMPA in patients with severe hepatic impairment is not recommended, and dosage adjustments are recommended in patients with mild or moderate hepatic impairment. Renal Impairment Dose adjustment is not required in patients with mild renal impairment. FYCOMPA should be used with caution in patients with moderate renal impairment, and slower titration may be considered. Use in patients with severe renal impairment or patients undergoing hemodialysis is not recommended. DRUG ABUSE AND DEPENDENCE Controlled Substance FYCOMPA contains perampanel and is listed as a Schedule III controlled substance. Abuse Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological or physiological effects. Drug addiction, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and drug addiction are separate and distinct from physical dependence (for example, abuse may not be accompanied by physical dependence). Studies of human abuse potential were performed to evaluate the abuse potential of FYCOMPA (8 mg, 24 mg, and 36 mg) as compared to alprazolam C-IV (1.5 mg and 3 mg), and oral ketamine C-III (100 mg) in recreational polydrug users. Supra-therapeutic doses of FYCOMPA 24 and 36 mg produced responses for “Euphoria” that were similar to ketamine 100 mg and alprazolam 3 mg. For “High,” FYCOMPA 24 mg and 36 mg produced responses comparable to ketamine 100 mg and significantly higher than both doses of alprazolam on a visual analog scale (VAS). “Drug Liking,” “Overall Drug Liking,” and “Take Drug Again” for FYCOMPA were each statistically lower than ketamine 100 mg. In addition, for “Bad Drug Effects,” FYCOMPA 24 mg and 36 mg produced responses significantly higher than ketamine 100 mg. For “Sedation,” FYCOMPA 24 and 36 mg produced responses similar to alprazolam 3 mg and higher than ketamine 100 mg. Additionally, on VAS measures related to dissociative phenomena such as “Floating,” “Spaced Out,” and “Detached,” FYCOMPA at supra-therapeutic doses produced responses similar to ketamine 100 mg and greater than both doses of alprazolam tested. Of note, due to somnolence a number of subjects had missing data around Tmax of FYCOMPA. The above described data might represent an underestimate of FYCOMPA’s effects. The duration of effects of higher doses of FYCOMPA on the majority of measures was much greater than alprazolam 3 mg and ketamine 100 mg. In this study, the incidence of euphoria following FYCOMPA administration 8 mg, 24 mg, and 36 mg was 37%, 46%, 46%, respectively, which was higher than alprazolam 3 mg (13%) but lower than ketamine 100 mg (89%). Dependence Physical dependence is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. The potential for FYCOMPA to produce withdrawal symptoms has not been adequately evaluated. OVERDOSAGE There is limited clinical experience with FYCOMPA overdose. The highest reported overdose (approximately 264 mg) was intentional. This patient experienced serious adverse reactions of altered mental status, agitation, and aggressive behavior and recovered without sequelae. In general, the adverse reactions associated with overdoses were similar to the reactions at therapeutic doses with dizziness reported most frequently. There were no reported sequelae. There is no available specific antidote to the overdose reactions of FYCOMPA. In the event of overdose, standard medical practice for the management of any overdose should be used. An adequate airway, oxygenation, and ventilation should be ensured; monitoring of cardiac rhythm and vital sign measurement is recommended. A certified poison control center should be contacted for updated information on the management of overdose with FYCOMPA. Due to its long half-life, the reactions caused by FYCOMPA could be prolonged.

Translational Research Highlighted in Today’s Plenary Session Continued from front cover

The topics and speakers are:

Wilson

Pradhan

503

Opioid Receptor Modulation of Headache — Amynah Pradhan, PhD OPEN TO BELOW University of Illinois at Chicago, Chicago, IL 500s 504 505 506

507

B A

508

510 512 513 514

516

Coming of Age: Clinical Implementation of Metagenomics for Diagnosis in Meningitis and Encephalitis — Michael R. Wilson, MD University of California, San Francisco, San Francisco, CA

Mehler

Down

502B

502A

Shining a Light on Early Stress Responses and LateOnset Disease Vulnerability — Mark F. Mehler, MD, FAAN Albert Einstein College of Medicine, New York, NY

517

501A

511A

501B

511B

501C

511C

518

515A

515B

519

8B 30 8A 30 9B 30

7 30 6B 30 6A 30 Do wn

402B

405

402A

5 401

403A

403B

410

411 THEATER

409B 408A

404A 406A

408B

Do wn

409A

Down

OPEN TO BELOW

407

404B 406B

400s

Don’t Forget to Use the Conferences App to Get the Most out of Your Week Whether you have an iPhone, iPad, or Android, be sure and download the new AAN Conferences Mobile App. Simply visit AAN.com/view/MobileApp and within minutes you can be locating your favorite sessions or events; planning, customizing, and modifying your schedule; and connecting with colleagues.

Features:

New! Find and connect with other conference attendees New! Improved filters allow you to search by programs, topics, and tracks Browse program details, speakers, and social/networking events Access program slides and syllabi Search scientific abstracts Create an itinerary and customize your schedule View room locations and hotel map Submit your program evaluations to earn CME Explore the Los Angeles City Guide

The AAN Conferences Mobile App is sponsored by Sunovion Pharmaceuticals Inc.

Saturday, April 21, 2018 • AANextra

Kuhle

Monitoring Multiple Sclerosis Using Blood Neurofilament Light Protein — Jens Kuhle, MD University Hospital of Basel Oberwil, Switzerland 

Exhibit Hall Opens Tomorrow—Don’t Miss These Highlights This year’s Exhibit Hall promises to be the biggest, most dynamic Annual Meeting Exhibit Hall yet. Beginning tomorrow at 11:30 a.m. you’ll find hundreds of opportunities to meet organizations and learn about exciting new products and services that can help you do your job better and provide the best possible care for patients.

Highlights:

AAN’s Innovation Hub Stretch your brain in new directions at this creative and interactive area featuring unique physician-led presentations, teleneurology demonstrations, daily paint and wine sessions, and more! Career Fair Neighborhood Learn about career opportunities available nationwide. Buzz Café This new area is a great spot to reconnect with colleagues while enjoying a complimentary caffeinated beverage. Technology Pavilion Experience cutting-edge technology that can change the way you care for patients. Association Neighborhood Visit with our association partners who are fighting to further disease awareness and help raise funds to find cures. Charging Hubs Charge your devices while you check in with your office, catch up on emails, or just relax in these comfortable areas. Daily Complimentary Lunches Lunch will be provided in the Exhibit Hall on open days.

Hours: Sunday, April 22, 11:30 a.m.–4:00 p.m. Opening lunch reception: 11:30–1:00 p.m. Sponsored by Celgene Corporation

Monday, April 23, 11:30 a.m.–6:00 p.m. Networking reception: 4:30 p.m.–6:00 p.m. Sponsored by Celgene Corporation

Tuesday, April 24, 11:30 a.m.–4:00 p.m. Wednesday, April 25, 11:30 a.m.–3:00 p.m. Visit AAN.com/conferences-community/annual-meeting/ exhibits-advertising-industry for a daily schedule of events. 

COME CELEBRATE THE

1-YEAR ANNIVERSARY JOIN US AT BOOTH

1802

Look for Complimentary Shuttle Service at Select Hotels Annual Meeting attendees at select hotels that were booked within the official AAN housing block will receive complimentary shuttle service throughout the week between their hotel and the Los Angeles Convention Center. Qualifying attendees should look for a picture of a bus on their badges. Shuttle buses will feature complimentary WiFi, courtesy of Teva CNS.

Hotels Not Offering Shuttle Service The following hotels are located within easy walking distance to the convention center and will not offer shuttle service: Courtyard by Marriott LA Live Hotel Figueroa Hotel Indigo Downtown JW Marriott Los Angeles LA Live

Luxe City Center Hotel Residence Inn by Marriott Los Angeles LA Live The Ritz-Carlton, Los Angeles

ADA Assistance Attendees requiring ADA assistance should contact (619) 921-0307 at least two hours prior to their need. 

Attendees who did not book a hotel within the official AAN housing block may purchase a shuttle pass through Annual Meeting Registration in the West Lobby of the Los Angeles Convention Center.

18: AAN.com Launch Ad—Half Page Horizontal> AN Placed in AANnews 8.25 x 5.25 +0.125 bleed, 4C

Your life is personalized...

now AAN.com is too. Log in today AAN.com/memberprofile

Saturday, April 21, 2018 • AANextra

VISIT US AT BOOTH #1202

TO LEARN MORE ABOUT GRT

GENE REPLACEMENT THERAPY:

A GENETIC EVOLUTION from Mendel’s work based in nature to notable advancements in medicine

We’ve come a long way since Mendel first laid the foundation of genetics— today, gene replacement therapy (GRT) is being investigated as a therapeutic approach that may have the potential to treat monogenic diseases at their source.1,2

References:1. Gayon J. From Mendel to epigenetics: history of genetics. C R Biol. 2016;339(7-8):225-230. 2. Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351-360. © 2018 AveXis, Inc. All Rights Reserved. US-UNB-18-0039 04/18

This Week’s “Best of” Scientific Platform Sessions Highlight Top-scoring Abstracts This week’s “Best of” Scientific Platform Sessions offer perfect lead-ins to the plenary sessions that immediately follow. “Best of” will bring together the top four scoring abstracts in a topic, as rated by the topic reviewers. At the conclusion of each session, attendees will have an opportunity to interact with the authors in a smaller, more intimate setting.

“Best of” Session: Cerebrovascular Disease and Interventional Neurology

“Best of” Session: Clinical Trial Updates in Neuromuscular Disorders

Sunday, April 22, 8:00 a.m.–9:00 a.m. preceding the Presidential Plenary Session . . . . . 408B

Thursday, April 26, 8:00 a.m.–9:00 a.m. preceding the Controversies in Neurology Plenary Session . . . . . . . . . . . . . . . . 408B

“Best of” Session: Epilepsy/Clinical Neurophysiology (EEG) Monday, April 23, 8:00 a.m.–9:00 a.m. preceding the Contemporary Clinical Issues Plenary Session . . . . . . . . . . . . . . . . 408B

“Best of” Session: Headache

“Best of” Session: MS and CNS Inflammatory Diseases Friday, April 27, 8:00 a.m.–9:00 a.m. preceding the Neurology in Review Plenary Session . . . . . . . . . West Exhibit Hall B 

Tuesday, April 24, 8:00 a.m.–9:00 a.m. preceding the Clinical Trials Plenary Session . . . . 515B

“Best of” Session: Movement Disorders Wednesday, April 25, 8:00 a.m.–9:00 a.m. preceding the Frontiers in Neuroscience Plenary Session . . . . . . . . . . . . . . . . 408B

A N INDU S T RY THERAPEU T I C UPDAT E FROM G E H E A LT H CA R E “ Why aim for earlier diagnosis of neurodegenerative disorders?” We’ve all heard it. Now we’re talking about it. Catch this lively discussion on the impact of early diagnosis.

The great diagnosis debate View video of the debate online at: gehealthcare.com/talkingtime

#TalkingTime Saturday, April 21, 2018, 8:00 PM PT. Platinum Ballroom, JW Marriott Hotel

This event is not part of the 2018 American Academy of Neurology Annual Meeting. CME credits will not be given by any accredited organizations for attending this event. March 2018 JB56403US

Get Connected to Synapse at the Member Experience: Personalize Your Journey Experiential Learning Area More than half of AAN members belong to one or more of the 45+ sections and consortiums and their associated open or private SynapseSM Online Communities. If you’re not already one of them, then now’s your chance to find out how you can be a part of neurology’s global conversation! Stop by the Member Experience Experiential Learning Area near the West Lobby of the Los Angeles Convention Center all week long to learn more about Synapse, the AAN’s memberonly, online platform where members can partner with colleagues; engage in conversation; exchange ideas; and share

scientific, practice, and professional insights. Section and consortium members can participate in scientific abstract reviews, education course proposals, and even collaborations on guidelines and advocacy efforts. While there, learn how you can stand out on Synapse with the new contributor badges. The more you contribute— be it posting a new discussion or replying to existing posts, adding photos or enhancing your profile’s biography, or submitting and reading library items— the more you get recognized. Ask AAN staff how you can stand out! 

Enjoy These Highlights of the Member Experience Experiential Learning Area Stop by to get connected, engaged—and even recognized— as a valued AAN member: Experience the new AAN.com to see how it’s personalized just for you—then compete with your colleagues to see who best knows their way around the site Update your AAN profile and get your profile picture taken Learn about all the opportunities to increase your engagement with the Academy See if you qualify to elevate your membership status to the premier Fellow of the American Academy of Neurology (FAAN) Check out the recognition walls and congratulate your deserving colleagues Win cool giveaways

CHP: 17 Axon Registry Ad—Half Page Horizontal> AN Placed in AANnews 8.25 x 5.25 +0.125 bleed, 4C

The Axon Registry: Insightful. Practical. Secure. Welcome to the Axon Registry®—an exclusive benefit for AAN members. Participate in the registry so you can: • Measure and improve the quality of your care • Meet PQRS/Quality reporting requirements, reduce administrative burden • Qualify for MOC Part IV Improvement in Medical Practice Clinical Module • Use data to demonstrate value to payers

The Axon Registry is ready to serve you! AAN.com/view/axon

TWEETS OF THE DAY AAN @AANMember

hrilled to see all the #FutureNeurologists T at the #BrainHealthFair today. @ConventionLA! #AANAM

Pearce Korb MD @drpearcekorb

Welcome to the City of Braingels. This week thousands of neurologists descend on #LA for the 70th American Academcy of Neurology Annual Meeting #AANAM. As always, I'm excited about all the learning, discovery & community it brings. http://ow.ly/yxc950h8Csb @AANMember @AANPublic

Altaf Saadi @AltafSaadiMD

Meeting amazing patient advocates at #AAN #BrainHealthFair - @robertcbowlesjr told me how we can move from using language of “caregiver” to “care-partner.” People living w/ #dementia can be partners in their care! His website: http://lbdlivingbeyonddiagnosis.com/ index.html #LewyBodyDementia @AANMember

Orly Avitzur MD MBA @OrlyA

Is this original @drpearcekorb art? If so, it should be made into posters and put on sale, it's so cool. What do you think @ABFbrain? #CityofBraingels

INDUSTRY THERAPEUTIC UPDATE FROM AKCEA THERAPEUTICS*: CHARTING THE COURSE

in Diagnosis of Rare Peripheral Neuropathies Monday, April 23, 2018 7:00 pm | Doors Open 6:30 pm

Westin Bonaventure | Beaudry B | Lobby Level 404 S Figueroa Street | Los Angeles, CA

Please visit register.chartingthecoursepn.com to register for this event. Join Sami Khella, MD, Chair, and our expert faculty panel at this industry therapeutic update where we will discuss rare peripheral neuropathies, including chronic inflammatory demyelinating polyneuropathy, hereditary ATTR amyloidosis, and Charcot-Marie-Tooth disease. This interactive session will illustrate diagnostic challenges and provide guidance toward making a differential diagnosis among these rare neuropathies. Stop by Akcea booth #707 for more information!

Moderator: Sami Khella, MD Professor of Clinical Neurology Chief Department of Neurology Penn Presbyterian Medical Center Philadelphia, PA

*Pursuant to a potential transaction involving a collaboration with Ionis Pharmaceuticals, Inc., which remains subject to stockholder approval and customary closing conditions. Please note that this is a promotional, non-CME program, and no CME credits will be given for attendance. This event is not sponsored or endorsed by AAN. ©2018 Akcea Therapeutics, Inc. All rights reserved. TTR-084 04/18

If You’re New to the Annual Meeting, These Opportunities Are for You! There’s no better way to settle into your new Annual Meeting experience than to attend one of these informative and interactive opportunities:

Navigating the AAN Conference Mobile App and Convention Center Tour Saturday, 12:00 p.m.–12:30 p.m. Location: HeadTalks Stage Host: Carlayne E. Jackson MD, FAAN Learning, networking, and engagement opportunities How to use the AAN Conference Mobile App (download the app at AAN.com/view/MobileApp) How to navigate the Los Angeles Convention Center

New! Bits & Bites Series Saturday–Thursday, 3:00 p.m. Location: First-time Attendee and Senior Member Lounge Stop by to grab a snack and participate in brief 10-minute presentations on specific items of interest going on throughout the week, volunteer opportunities, and valuable AAN resources. 

VISIT OUR BOOTH #509 The Mount Sinai Hospital is ranked No. 16 in Neurology & Neurosurgery by U.S. News & World Report, 2017-18. Our world-class specialists are commi ed to the discovery of new treatments for neurological conditions and hold faculty appointments at the Icahn School of Medicine at Mount Sinai, ranked among the nation’s top medical schools by U.S. News & World Report. • Comprehensive Stroke Center • Bendheim Parkinson and Movement Disorders Center • Corinne Goldsmith Dickinson Center for Multiple Sclerosis • Center for Headache and Facial Pain • Center for Cognitive Health and Alzheimer’s Disease Research • Parkinson’s Foundation Center of Excellence • Neuromuscular Disease Division • Neuro-Otology and Neurogenetics Division • Neuro-Infectious Diseases and NeuroAIDS Program • Epilepsy Program • Pediatric Neurology Division • Neuro-Oncology Program • Neuro-Ophthalmology Program • Health Outcomes and Knowledge Translation Research Division

1-800-MD-SINAI • mountsinai.org/neurology

INDUSTRY THERAPEUTIC UPDATE FROM ADAMAS PHARMACEUTICALS, INC. HOW CAN WE

FIGHT DYSKINESIA IN

PARKINSON’S DISEASE? Join us for personal and professional perspectives on Parkinson’s disease, with a focus on dyskinesia. This dynamic program features a roundtable discussion among leading experts in the treatment of dyskinesia in Parkinson’s disease, as well as a heartfelt keynote presentation by the daughter of the late, great Muhammad Ali, who lived with Parkinson’s disease for years before he was diagnosed. Don’t miss this opportunity to hear engaging personal and professional perspectives on the impact and management of Parkinson’s disease, with a focus on dyskinesia.

TUESDAY, APRIL 24TH 2018

7:00 PM–10:00 PM REGISTRATION BEGINS AT 6:30 PM

San Diego Ballroom • Westin Bonaventure Hotel • Los Angeles, CA COMPLIMENTARY DINNER WILL BE SERVED

GOCOVRI (amantadine) extended release capsules is the first and only medicine approved by the FDA for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2. WARNINGS AND PRECAUTIONS Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (eg, driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities. Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

PRESENTERS

KEYNOTE SPEAKER

Rajesh Pahwa, MD

Laverne & Joyce Rider Professor of Neurology Kansas Medical Center Chief, Parkinson Disease & Movement Disorder Division Director, Parkinson Foundation Center of Excellence Kansas City, KS

Daniel E. Kremens, MD, JD Associate Professor of Neurology Department of Neurology Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia, PA

Stuart Isaacson, MD

Associate Professor of Neurology Herbert Wertheim College of Medicine Florida International University Miami, FL Director, Institute for Neurodegenerative Diseases of Florida Parkinson’s Disease and Movement Disorders Center of Boca Raton Alzheimer’s and Memory Disorders Center of South Florida Boca Raton, FL

MARYUM ALI Daughter of Muhammad Ali “My Father’s Journey, and What It Means to Me”

IMPORTANT SAFETY INFORMATION (cont.) WARNINGS AND PRECAUTIONS (cont.) Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases. Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose. Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI. Impulse Control/Compulsive Behaviors: Patients may experience urges (eg, gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications. ADVERSE REACTIONS The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension. DRUG INTERACTIONS Other Anticholinergic Drugs: The dose of GOCOVRI should be reduced if atropine-like effects are observed. Drugs Affecting Urinary pH: The pH of the urine has been reported to influence the excretion rate of amantadine. Monitor for efficacy or adverse reactions under conditions that alter the urine pH. Alcohol: Concomitant use with alcohol is not recommended, as it may increase the potential for CNS effects such as dizziness, confusion, lightheadedness, and orthostatic hypotension. Please see Brief Summary of full Prescribing Information on the next page.

Please visit us at Booth 703 For more information and to preregister for this program, please visit

www.fightdyskinesia.com Seating is limited, so preregistration is recommended. This promotional, non-CME program is intended only for healthcare professionals involved in the treatment of people with Parkinson’s disease. This is not an AAN-endorsed event.

GOCOVRI™ (amantadine) extended release capsules Brief Summary of full Prescribing Information. See full Prescribing Information. Rx Only. INDICATIONS AND USAGE: GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. CONTRAINDICATIONS: Contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2 WARNINGS AND PRECAUTIONS: Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. Patients may not perceive warning signs, such as excessive drowsiness, or they may report feeling alert immediately prior to the event. In controlled clinical trials, somnolence and fatigue were reported in 4% vs. 1% of patients treated with GOCOVRI or placebo, respectively. Before initiating treatment with GOCOVRI, advise patients of the potential to develop drowsiness and specifically ask about factors that may increase the risk for somnolence with GOCOVRI, such as concomitant sedating medications or the presence of a sleep disorder. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued. If a decision is made to continue GOCOVRI, patients should be advised not to drive and to avoid other potentially dangerous activities. There is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living or daytime somnolence. Suicidality and Depression: In controlled clinical trials, suicidal ideation or suicide attempt was reported in 2% vs. 0%; depression or depressed mood 6% vs. 1%; confusional state 3% vs. 2%; apathy 2% vs. 0%, in patients treated with GOCOVRI or placebo, respectively. Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression. Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. In controlled trials, the incidence of patients who experienced visual hallucination, auditory hallucination, delusions, illusions, or paranoia was 25% vs 3%; hallucinations caused discontinuation of treatment in 8% vs.0%; in patients treated with GOCOVRI or placebo, respectively. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases. Dizziness and Orthostatic Hypotension: In controlled clinical trials, 29% vs. 2% experienced dizziness, syncope, orthostatic hypotension, presyncope, postural dizziness or hypotension; and 3% vs. 0% discontinued study treatment because of dizziness, postural dizziness, or syncope; in patients receiving GOCOVRI or placebo, respectively. Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose. Concomitant use of alcohol with GOCOVRI is not recommended. Withdrawal-Emergent Hyperpyrexia and Confusion: A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central dopaminergic tone. Abrupt discontinuation of GOCOVRI may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. If possible, avoid sudden discontinuation of GOCOVRI. Impulse Control/Compulsive Behaviors: Patients can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including GOCOVRI, that increase central dopaminergic tone. In some cases, these urges were reported to have stopped when the dose was reduced or the medication was discontinued. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of such urges, and to consider dose reduction or stopping GOCOVRI treatment. ADVERSE REACTIONS: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. GOCOVRI was evaluated in two double-blind, placebo-controlled efficacy trials of similar design and population: Study 1 (123 patients) and Study 2 (75 patients). The study population was approximately 56% male and 94% white, with a mean age of 65 years (age range from 34 years to 82 years). The mean duration of levodopa-induced dyskinesia was 4 years (range 0.1 to 14 years). Active treatment started at 137 mg once daily for one week, followed by a dose increase to 274 mg once daily. The treatment duration was 25 weeks for Study 1 and 13 weeks for Study 2. Study 1 was stopped prematurely unrelated to safety, with 39/100 patients (safety population) treated with GOCOVRI for 24 weeks. The most common adverse reactions reported in >10% of GOCOVRI-treated patients and more frequently than on placebo were: hallucination, dizziness, dry mouth, peripheral edema, constipation, falls, and orthostatic hypotension. The overall rate of discontinuation because of adverse reactions was 20% vs. 8% for patients treated with GOCOVRI or placebo, respectively. Adverse reactions that led to treatment discontinuation in at least 2% of patients were hallucination (8% GOCOVRI vs. 0% placebo), dry mouth (3% GOCOVRI vs. 0% placebo), peripheral edema (3% GOCOVRI vs. 0% placebo), blurred vision (GOCOVRI 3% vs.0% placebo), postural dizziness and syncope (GOCOVRI 2% vs. 0% placebo), abnormal dreams (GOCOVRI 2% vs. 1% placebo), dysphagia (GOCOVRI 2% vs. 0% placebo), and gait disturbance (GOCOVRI 2% vs. 0% placebo). Pooled Analysis of Adverse Reactions Reported for ≥ 3% of Patients Treated with GOCOVRI 274 mg (N=100) or placebo (N=98), respectively: Psychiatric disorders: visual and/or auditory hallucination (21%, 3%); anxiety and/or generalized anxiety (7%, 3%); insomnia (7%, 2%); depression/depressed mood (6%, 1%); abnormal dreams (4%, 2%); confusional state (3%, 2%). Nervous system disorders: dizziness (16%, 1%); headache (6%, 4%); dystonia (3%, 1%). Gastrointestinal disorders: dry mouth (16%, 1%); constipation (13%, 3%); nausea (8%, 3%); vomiting (3%, 0%). General disorders and administration site conditions: peripheral edema (16%, 1%); gait disturbance (3%, 0%). Injury, poisoning and procedural complications: fall (13%, 7%); contusion (6%, 1%) Infection and infestations: urinary tract infection (10%, 5%). Skin and

subcutaneous tissue disorders: livedo reticularis (6%, 0%); pigmentation disorder (3%, 0%). Metabolism and nutrition disorders: decreased appetite (6%, 1%). Vascular disorders: orthostatic hypotension, including postural dizziness, syncope, presyncope, and hypotension (13%, 1%). Eye disorders: blurred vision (4%, 1%); cataract (3%, 1%); dry eye (3%, 0%). Musculoskeletal and connective tissue disorders: joint swelling (3%, 0%), muscle spasm (3%, 0%). Reproductive system and breast disorders: benign prostatic hyperplasia—all male (6%, 2%). Respiratory, thoracic and mediastinal disorders: cough (3%, 0%). Other clinically relevant adverse reactions observed at <3% included somnolence, fatigue, suicide ideation or attempt, apathy, delusions, illusions, and paranoia. Difference in the Frequency of Adverse Reactions by Gender in Patients Treated with GOCOVRI. Adverse reactions reported more frequently in women (n=46) vs. men (n=54), were: dry mouth (22% vs.11%), nausea (13% vs. 4%), livedo reticularis (13% vs. 0%), abnormal dreams (9% vs. 0%) and cataracts (7% vs. 0%), respectively. Men vs. women reported the following adverse reactions more frequently: dizziness (20% vs. 11%), peripheral edema (19% vs. 11%), anxiety (11% vs. 2%), orthostatic hypotension in (7% vs. 2%) and gait disturbance (6% vs. 0%), respectively. Difference in the Frequency of Adverse Reactions by Age in Patients Treated with GOCOVRI. Hallucinations (visual or auditory) were reported in 31% of patients age 65 years and over (n=52), vs.10 % in patients below the age of 65 years (n=48). Falls were reported in 17% of patients age 65 and over, vs. 8% of patients below age 65. Orthostatic hypotension was reported in 8% of patients age 65 and over, compared to 2% of patients below age 65. DRUG INTERACTIONS: Other Anticholinergic Drugs: Products with anticholinergic properties may potentiate the anticholinergic-like side effects of amantadine. The dose of anticholinergic drugs or of GOCOVRI should be reduced if atropine-like effects appear when these drugs are used concurrently. Drugs Affecting Urinary pH: The pH of the urine has been reported to influence the excretion rate of amantadine. Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate), and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). Since the excretion rate of amantadine increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. Alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse reactions. Monitor for efficacy or adverse reactions under conditions that alter the urine pH to more acidic or alkaline, respectively. Live Attenuated Influenza Vaccines: Due to its antiviral properties, amantadine may interfere with the efficacy of live attenuated influenza vaccines. Therefore, live vaccines are not recommended during treatment with GOCOVRI. Inactivated influenza vaccines may be used, as appropriate. Alcohol: Concomitant use with alcohol is not recommended, as it may increase the potential for CNS effects such as dizziness, confusion, lightheadedness, and orthostatic hypotension, and may result in dose-dumping. USE IN SPECIFIC POPULATIONS: Pregnancy: There are no adequate data on the developmental risk associated with use of amantadine in pregnant women. Based on animal data, may cause fetal harm. Lactation: Amantadine is excreted into human milk, but amounts have not been quantified. There is no information on the risk to a breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for GOCOVRI and any potential adverse effects on the breastfed infant from GOCOVRI or from the underlying maternal condition. Pediatric Use: Safety and effectiveness of GOCOVRI in pediatric patients have not been established. Geriatric Use: In Phase 3 clinical trials, the mean age of patients at study entry was 65 years. Of the total number of patients in clinical studies of GOCOVRI, 46% were less than 65 years of age, 39% were 65-74 years of age, and 15% were 75 years of age or older. Hallucinations and falls occurred more frequently in patients 65 years of age or older, compared to those less than 65 years of age. No dose adjustment is recommended on the basis of age. GOCOVRI is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Renal Impairment: GOCOVRI is contraindicated for use in patients with end-stage renal disease (creatinine clearance values lower than 15 mL/min/1.73 m2). A 50% dose reduction of GOCOVRI dosage to a starting daily dose of 68.5 mg daily for a week, followed by a daily maintenance dose of 137 mg is recommended in patients with moderate renal impairment (creatinine clearance between 30 and 59 mL/min/1.73 m2). For patients with severe renal impairment (creatinine clearance between 15 and 29 mL/min/m2), a daily dose of 68.5 mg is recommended. Overdosage: Deaths have been reported from overdose with amantadine immediaterelease. The lowest reported acute lethal dose was 1 gram of amantadine hydrochloride (equivalent to 0.8 g amantadine). Acute toxicity may be attributable to the anticholinergic effects of amantadine. Drug overdose has resulted in cardiac, respiratory, renal, or central nervous system toxicity. Pulmonary edema and respiratory distress (including adult respiratory distress syndrome, ARDS) have been reported with amantadine; renal dysfunction, including increased BUN and decreased creatinine clearance, can occur. Central nervous system effects that have been reported with overdose include agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, tremor, disorientation, depersonalization, fear, delirium, psychotic reactions, lethargy, and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has occurred with amantadine overdose. For acute overdosing, general supportive measures should be employed along with immediate gastric decontamination if appropriate. Give intravenous fluids if necessary. The excretion rate of amantadine increases with acidification of urine, which may increase the elimination of the drug. Monitor patients for arrhythmias and hypotension. Electrocardiographic monitoring may be needed after ingestion because arrhythmias have been reported after overdose, including arrhythmias with fatal outcomes. Adrenergic agents, such as isoproterenol, in patients with an amantadine overdose has been reported to induce arrhythmias. Monitor blood electrolytes, urine pH, and urinary output. Although amantadine is not efficiently removed by hemodialysis, this procedure may be useful in the treatment of amantadine toxicity in patients with renal failure. Gocovri, the Gocovri logo, Adamas, and the Adamas logo are trademarks of Adamas Pharmaceuticals, Inc. or its related companies. © 2018 Adamas Pharmaceuticals, Inc. or its related companies. All rights reserved. GOC-0202 03/18

BRAIN HEALTH FAIR QUOTABLE QUOTES Nadya “I'm learning about how the brain works and also especially about concussion and how it affects the brain. It’s really interesting and I would like to be a neurologist someday.”

Angie “I am amazed, actually, by the pockets of really interesting things, especially this one [on boxing and Parkinson’s] because I'm a boxing trainer and this looks amazing and I need to know more about it and Parkinson’s. I was watching one of the lectures, which was very interesting and very informative. I'm just working my way slowly around. It's a wonderful optportunity, it kept coming up on my Facebook page and I wrote it down to go to get every possible thing I can get from that. Thank you. This is wonderful to meet wonderful people with the same mindset.”

Gloria “I got to go to the pharmacy booth because I had surgery a week ago. You know how it is, how your doctor, when you talk, it was very fast. I understand that they were very busy so I talked to the pharmacy here about my eyes. It's helpful, yes, and very nice. It is very good.”

Michael “Our teacher wants to understand the brain more because it’s the following chapter [in our textbook], the neurons and everything. I did actually learn a lot. This is more interactive, and we got to learn how the brain actually works. I'm interested in, like, physical therapy and I visited the booth over there and got my questions answered.”

Who Will Win This Year’s Coveted Neurobowl Trophy? Find Out Tonight! Celebrating 70 Years of the AAN at Universal Studios Sunday Night You won’t want to miss the excitement of tonight’s premier happening: the always popular Neurobowl®, hosted by AAN former president Thomas R. Swift, MD, FAAN, along with Kapil D. Sethi, MD, FRCP, FAAN, and Bert B. Vargas, MD, FAAN. Free to all registered Annual Meeting attendees, this popular game show-style event will begin at 6:00 p.m. in South Exhibit Hall K. Stop by to enjoy delicious food and beverages as the best and brightest in neurology vie for the coveted trophy. 

Don’t Forget to Pick Up Your Tickets by 4:00 p.m. Sunday! If you secured your free, limited quantity ticket—or purchased additional tickets—to attend this year’s family friendly kick-off to the Annual Meeting, then don’t forget to stop by the Universal Studios Will Call booth in the West Lobby of the Los Angeles Convention Center by no later than 4:00 p.m. Sunday to pick them up. Pre-reserved gratis tickets that are not picked up by 4:00 p.m. will be released for rush line. The special 70th Anniversary Celebration will be held at Universal Studios and all tickets include transportation to/from the event, delicious food and beverages all evening, and rides and studio tour. Learn more at AAN.com/view/70Anniversary.

Today’s Boxed Lunch Menu Saturday, April 21

Lunch Options Locations: South Lobby and West Hall A Choose from two convenient locations, each featuring two box lunch options. Grab your lunch and enjoy while taking in talks on the Experiential Learning Area stages near the South Lobby, or pick up your lunch and head to the Poster Discussion Sessions in West Hall A. Option I: HHGlass noodle salad with chicken ~DF, GF HHNapa cabbage, wonton crisps on side, shredded carrots, glass noodles, edamame, and Asian vinaigrette ~GF, DF HHChocolate covered macaroons ~GF HHWhole fresh fruit ~V, VG, DF, GF

V = Vegetarian GF = Gluten free VG = Vegan DF =Dairy free

Saturday, April 21, 2018 • AANextra

Option II: HHGrilled vegetables and garlic hummus wrap with GF tortilla ~DF, GF, V, VG HHThree bean and basil salad with white balsamic dressing ~DF, GF, V, VG

HHMacaroons ~GF, V, VG HHWhole fresh fruit ~V, VG, DF, GF 

How well do you know migraine prevention? Nearly 40% of Americans who suffer from migraine could be appropriate for preventive treatment. Teva is committed to advancing the science and education of migraine. Together, we can reinvent the migraine paradigm.

Visit MoreToMigrainePrevention.com to learn more

ÂŠ2018 Teva Pharmaceuticals USA, Inc. MIG-40600 March 2018

Test your knowledge with The Migraine Prevention Challenge at Booth 1261.

Build, Expand Your Leadership Potential—All Week Long The AAN is committed to helping build and expand your leadership potential and this week’s lineup of Leadership University offerings reflects this commitment. These special programs—many which are free and require no pre-registration—address critical leadership skills needed in today’s health care environment.

Free—No Advance Registration Required

Advance Registration Required

These sessions are free and included with your Annual Meeting registration; however, seating is limited. Use the AAN Conference Mobile App at AAN.com/view/MobileApp to add these programs to your itinerary.

Pre-registration is required to attend these programs, and seating is limited. To enroll, log in to www4.cmrreg.com/ aanam2018 and select your desired program(s) from the list of optional AAN special programs.

Leadership Challenges in Practice

Women in Leadership

Saturday, 12:00 p.m.–4:00 p.m. Director: Brad C. Klein, MD, MBA, FAAN This program discusses relationship development and communication techniques to improve leadership effectiveness within an organization of any size.

Being a Resilient Leader: How Do You Lead the Change? Sunday, 1:00 p.m.–5:00 p.m. Directors: Heidi B. Schwarz, MD, FAAN, and Jennifer Rose Molano, MD, FAAN

Saturday, 7:00 a,m.–4:00 p.m. Directors: Janice M. Massey, MD, FAAN; Orly Avitzur, MD, MBA, FAAN; and Keri Bischoff and Julie Anderson, Gallupcertified Strengths Consultants This customized program will help participants understand how they uniquely influence and lead, and reveal a personalized look at leadership style. Participants will learn to lead and influence with more authenticity, confidence, and intention in areas of communication, negotiation, and work-life balance.

This course will empower neurologists to become leaders in their communities to increase personal engagement within one’s organization.

NEW! Mitigating the Impact of Unconscious Bias Workshop Monday, 1:00 p.m.–4:00 p.m. Director: Laraine Kaminsky, CEO, Global LK During this informative, participatory, and engaging workshop, faculty will explore the science of unconscious bias, with a specific focus on the impact of bias and resulting disparities in the health care sector.

NEW! Leadership in the Era of Burnout: A Practical Approach to Becoming a True Physician Leader Tuesday, 1:00 p.m.–3:00 p.m. Director: Terrence L. Cascino, MD, FAAN The challenge of being a leader is complicated by a high rate of burnout. This course will examine how to lead effectively and at the same time promote wellness.

Advanced Leadership Training: Preparing for Your Career’s Insurmountable Opportunities Wednesday, 1:00 p.m.–5:00 p.m. Directors: Robert C. Griggs, MD, FAAN; Richard Leider This highly interactive program will consider the strategies for finding and creating new opportunities for leadership in one’s career and life. Leaders from private practice and from academia will share their perspectives and consider ways of setting and reaching new goals. This workshop will bring together people from many career stages to consider how one can shift gears and pursue highly productive, generative, and creative activities as a practitioner, educator, or researcher.

Saturday, April 21, 2018 • AANextra

Educators’ Leadership Program Saturday, 1:00 p.m.–4:00 p.m. Director: Jaffar Khan, MD, FAAN Neurology clerkship and program directors are among the most important gatekeepers of our pipeline to careers in neurology. In many cases, these education leaders are responsible for the first contact with potential candidates for the future workforce in neurology. This course is designed to optimize the skill set of program/clerkship directors and associate program/clerkship directors that have been in their roles three to 10 years.

The Most Important Tool in Your Black Bag: Gallup StrengthsFinders Assessment Sunday, 1:00 p.m.–5:00 p.m. Directors: Keri Bischoff and Julie Anderson, Gallup-certified Strengths Consultants As a neurologist, you’re well educated and accomplished, but how well do you know yourself? StrengthsFinders™ is an online measure of personal talent that identifies areas of your greatest potential for building individual strengths. By capturing your top themes of talent, you’ll realize a language for how you uniquely come at the world.

NEW! Continuing Your Leadership Journey: Uncharted Waters Monday, 1:00 p.m.–3:00 p.m. Director: Barbara L. Hoese, President, Pentecore Coaching After successfully completing the AAN’s intensive leadership program, you set off equipped with new skills for leading. This course will refresh your skills and take your leadership to the next level.

Mentoring…Growing the Next Generation of Neurologist Tuesday, 1:00 p.m.–3:00 p.m. Director: Joanne L. Smikle, PhD, Principal, Smikle Training Services This session focuses on the competencies required to build strong developmental relationships.

NEW! Leadership Strengths in Neurology: The Data, Tools and Practical Application of Strengths for Leadership, Team Building, and Personal Development Wednesday, 1:00 p.m.–5:00 p.m. Directors: Keri Bischoff and Julie Anderson, Gallup-certified Strengths Consultants How can I improve my relationships professionally and socially? How can I contribute my strengths to team dynamics and performance? This workshop will focus on understanding the practical and specific application of Strengths. Strengths data in neurology will be shared to address your unique needs through interactive and guided discussions as we highlight tools to improve relationships and maximize team productivity. 

Applications Open for Four Intensive Training Programs These prestigious Leadership Programs require an application process and a time commitment for travel and training. Each one addresses critical leadership skills that are essential to the neurology profession and, in turn, essential to patient care. These programs also enhance participants’ leadership experience within the AAN specifically, providing future opportunity to participate and advance strategic priorities of the Academy in a way that also grows leadership competency. Visit AAN.com/view/Lead by June 4 to apply for: Emerging Leaders— Designed to identify, engage, and mentor early career members who are committed to professional, community, and society leadership. Transforming Leaders— Designed to identify and develop talent among experienced members. Practice Leadership— Designed to develop and hone the kind of unique leadership skills critical for today’s practicing neurologist to succeed and flourish. Women Leading in Neurology— Designed identify, engage, and mentor mid-career female member neurologists who are committed to professional, community, and society leadership.

Saturday, April 21, 2018 • AANextra

I’M AFRAID TO FAINT AGAIN Look carefully. This may be the face of neurogenic orthostatic hypotension (nOH). If your patients with a pre-existing neurodegenerative disorder are suffering from dizziness or other symptoms that improve upon sitting, they could have nOH.1-3 Patients with nOH may experience symptoms that can make daily tasks a challenge.3,4 Understanding the symptoms commonly associated with nOH may help in diagnosis and may provide a path for appropriate symptom management.4 Access information about identifying and managing nOH in your patients and register for updates at NOHmore.com—your online resource for understanding why nOH matters. References: 1. Freeman R. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615-624. 2. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22(2):79-90. 3. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72. 4. Low PA. Neurogenic orthostatic hypotension: pathophysiology and diagnosis. Am J Manag Care. 2015;21(suppl 13):s248-s257.

Medical Students and Residents: Help Build Your Careers in Research For medical students and residents who are interested in research, the AAN is offering new programming this year at the Annual Meeting. Components include training, mentoring, and networking designed to address the needs of pre- and early-career researchers. The AAN also provided scholarships to medical students and residents to allow them to take part in these programs and other special programming. Today is Young Investigator Day in the Research Corner: Moving Neurology Forward Experiential Learning Area, with programming running from 7:30 a.m. to noon. Highlights include a presentation on work-life balance in research at 8:25 a.m. by Amanda Peltier, MD, MS, and an investigator panel at 10:00 a.m. on how panel members launched their careers with NIH funding, private funding, AAN Research Program funding and/or government funding with Nicoline Schiess, MD; Daniel Claassen, MD; and An Hong Do, MD. Research careers in industry will be covered at 11:00 a.m. by Richard Rudick, MD, FAAN. Aasef Shaikh, MD, will discuss funding clinically oriented/translational research before the RO1 with consortium and foundation opportunities at 11:40 a.m. On Sunday, presentations in the Navigating Your Career Experiential Learning Area include “Research in Residency: How to Choose the Right Project,” at 7:45 a.m. by Roy E. Strowd III, MD, and “K Is for Career Development—Tips from Successful Applications for NIH Career Development Awards,” at 8:15 a.m. by Logan D. Schneider, MD. Programming on Monday in the Research Corner includes “Defining and Managing Your Message as an Early Career Researcher,” at 7:30 a.m. by Corey Fehnel, MD, and “Your CV Is Talking About You Behind Your Back, and Your LORs Are Too!” at 8:10 a.m. by Na Tosha N. Gatson, MD, PhD. 

2018 AAN Award Recipients Announced Congratulations to the recipients of the 2018 AAN awards. Most of these honorees will be celebrated with presentations of their awards during the Annual Meeting, and some will present papers at the following noted times. The American Academy of Neurology thanks the American Brain Foundation for its support through philanthropy of the American Academy of Neurology awards program. ALLIANCE AWARDS: FOUNDERS

Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Recipient: Ezequiel Gleichgerrcht, MD

ALLIANCE AWARDS: S. WEIR MITCHELL Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Recipient: Eric C. Landsness, MD, PhD

AMERICAN ACADEMY OF NEUROLOGY PRESIDENT’S AWARD

This award is given by the American Academy of Neurology President for outstanding service to the AAN and the profession of neurology.

Recipient: Lisa M. Shulman, MD, FAAN, Baltimore, MD

AMERICAN BRAIN FOUNDATION BOARD CHAIR’S AWARD

Sponsored by the American Brain Foundation.

Recipient: Richard P. Essey, San Francisco, CA

ASSOCIATION OF INDIAN NEUROLOGISTS IN AMERICA (AINA) LIFETIME ACHIEVEMENT AWARD

SIDNEY CARTER AWARD IN CHILD NEUROLOGY

JOHN DYSTEL PRIZE FOR MULTIPLE SCLEROSIS RESEARCH

Recipient: Richard S. Finkel, MD Nemours Children’s Hospital Orlando, FL Title: Spinal Muscular Atrophy Is a Treatable Neurodegenerative Disease

Recipient: Frederik Barkhof, MD, PhD

SHEILA ESSEY AWARD: AN AWARD FOR ALS RESEARCH

CLERKSHIP COORDINATOR RECOGNITION AWARD

Sponsored by the American Academy of Neurology, the American Brain Foundation and the ALS Association and supported through the philanthropy of the Essey Family and the ALS Association.

Recipients: Maryam Shakir, MPH, Miami, FL

Janet Lopez, Chicago, IL

Recipient: Timothy M. Miller, MD, PhD

CLERKSHIP DIRECTOR TEACHING AWARD Recipient: Rachel Marie E. Salas, MD, FAAN Baltimore, MD

COMMITMENT TO CURES AWARD

AWARD FOR CREATIVE EXPRESSION OF HUMAN VALUES IN NEUROLOGY

This award is sponsored by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology, the American Neurological Association, and the Child Neurology Society.

Recipient: Madaline B. Harrison, MD, Charlottesville, VA

A.B. BAKER AWARD FOR LIFETIME ACHIEVEMENT IN NEUROLOGIC EDUCATION

Funded by an endowment created by matching funds from the A.B. Baker Family Trust and Novartis Pharmaceuticals

FRANK A. RUBINO AWARD FOR EXCELLENCE IN CLINICAL NEUROLOGY TEACHING

The award is funded by an endowment created by matching funds from the Mayo Clinic Frank A. Rubino fund.

Recipient: Barbara S. Giesser, MD, FAAN, Los Angeles, CA

Sponsored by the American Brain Foundation.

Recipient: DeMaurice Smith, Executive Director, NFL Players Association, Washington, DC

NORMAN GESCHWIND PRIZE IN BEHAVIORAL NEUROLOGY

Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology.

Sponsored by the American Brain Foundation.

Recipient: Vinay Chaudhry, MD, MBA, CPE, FRCP, FAAN, Baltimore, MD

Sponsored by the American Academy of Neurology and National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society.

GEORGE C. COTZIAS LECTURE Recipient: Tallie Z. Baram, MD, PhD University of CA-Irvine, Irvine, CA

Recipient: Zachary A. Miller, MD

Title: How Early-life Experiences Sculpt Your Brain: From Molecules to Circuits

DREIFUSS-PENRY EPILEPSY AWARD

Sponsored by the American Academy of Neurology and endowed by members of the American Academy of Neurology Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Neuroscience; Ortho-McNeil Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma.

WAYNE A. HENING SLEEP MEDICINE INVESTIGATOR AWARD

Sponsored by the American Academy of Neurology and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening.

Recipient: Yo-El Ju, MD, MSCI Continued on page 36 u

Recipient: Kathryn A. Davis, MD, MS, FAES

Recipient: Steven Galetta, MD, FAAN New York, NY

Saturday, April 21, 2018 • AANextra

INTERNATIONAL SCHOLARSHIP AWARD Sponsored by the American Academy of Neurology.

Recipients: Zemen Tadesse Abu, Addis Ababa, Ethiopia

Vafa Alakbarzade, Plymouth, United Kingdom

Fabiola De Marchi, Novara, Italy

Federico Eberbach, Buenos Aires, Argentina

Arunmozhimaran Elavarasi, New Delhi, India

Nada Abdelhameed Elsaid, Mansoura, Egypt

Clare Angeli Enriquez, Manila, Phillipines

Kaushik Gowthaman, Chennai, India

Chiseko Ikenaga, Tokyo, Japan

Mariano Marrodan, Buenos Aires, Argentina

Sponsored by the American Academy of Neurology. Award not given for 2018.

MEDICAL STUDENT ESSAY AWARD— G. MILTON SHY AWARD Sponsored by the American Academy of Neurology.

Recipient: Benjamin D. Wissel

MEDICAL STUDENT ESSAY AWARD— ROLAND P. MACKAY AWARD Sponsored by the American Academy of Neurology.

Recipient: Yi Tong

MEDICAL STUDENT ESSAY AWARD— SAUL R. KOREY AWARD Sponsored by the American Academy of Neurology.

Recipient: Kirsten Martin

MOVEMENT DISORDERS RESEARCH AWARD

Sankaranarayanan Muthukani, Tamilnadu, India

Sponsored by the American Academy of Neurology, the Parkinson’s Foundation, and the American Academy of Neurology Movement Disorders Section and endowed by the Parkinson’s Foundation.

Divya M. Radhakrishnan, New Delhi, India

Recipient: Irene Litvan, MD, FAAN

Gerard Raimon M. Saranza, Manila, Phillipines

Elison Sarapura, Lima, Peru

Marianna Spatola, Barcelona, Spain

Irina Sharinova, Moscow, Russia

Chen-chen Tan, Qingdao, China

Joseph Kamtchum Tatuene, Blantyre, Malawi

Jiangtao Zhang, Beijing, China

Susanna M. Zuurbier, Amsterdam, The Netherlands

MITCHELL B. MAX AWARD FOR NEUROPATHIC PAIN

Sponsored by the American Academy of Neurology and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max.

Recipient: David M. Simpson, MD, FAAN

LAWRENCE C. MCHENRY AWARD: AN AWARD FOR THE HISTORY OF NEUROLOGY

Sponsored by the American Academy of Neurology.

Recipient: Bart TH Lutters, BSc

MEDICAL STUDENT ESSAY AWARD— EXTENDED NEUROSCIENCE AWARD

Saturday, April 21, 2018 • AANextra

NEURO-ONCOLOGY INVESTIGATOR AWARD

Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner.

Recipient: Milan G. Chheda, MD

NEURO-ONCOLOGY SCIENTIFIC AWARD

Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung.

Recipient: Scott R. Plotkin, MD, PhD

NEUROLOGY ® RESIDENT & FELLOW SECTION WRITING AWARD Recipients: Sheena Chew, MD, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Ivana Vodopivec, MD, PhD Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA Aaron L. Berkowitz, MD, PhD Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

NEUROENDOCRINE RESEARCH AWARD Sponsored by the American Academy of Neurology and supported by friends of Dr. Andrew Herzog.

Recipient: Ellen Mowry, MD, FAAN

NEUROSCIENCE RESEARCH PRIZE Funded by the American Academy of Neurology.

Recipients: Alex Remnitz

Jackie Stochel

Sarah Hoffman

CHILD NEUROLOGY NEUROSCIENCE RESEARCH PRIZE

Sponsored by the American Academy of Neurology and the Child Neurology Society.

Recipient: Amy Shteyman

MICHAEL S. PESSIN STROKE LEADERSHIP PRIZE

Sponsored by the American Academy of Neurology and endowed by Dr. Pessin’s family, friends, and colleagues.

Recipient: Glen Jickling, MD, MSc, FRCP(C)

PUBLIC LEADERSHIP IN NEUROLOGY AWARD

Sponsored by the American Brain Foundation.

Recipient: Temple Grandin, PhD, Fort Collins, CO

MRIDHA SPIRIT OF NEUROLOGY HUMANITARIAN AWARD

Sponsored by the American Brain Foundation and funded through the philanthropy of Dr. and Mrs. Mridha.

Recipient: Aaron L. Berkowitz, MD, PhD, Boston, MA

PRESIDENTIAL LECTURE Recipient: Francis S. Collins, MD, PhD Director of National Institutes of Health, Bethesda, MD Title: California Dreaming: BRAIN and Precision Medicine in 2018

POTAMKIN PRIZE FOR RESEARCH IN PICK’S, ALZHEIMER’S, AND RELATED DISEASES

Sponsored by the American Academy of Neurology and the American Brain Foundation and funded through the philanthropy of the Potamkin family.

Recipient: David A. Bennett, MD Continued on page 38 u

Being a teaching hospital makes us stronger. Being a teaching hospital for two great medical schools makes us NewYork-Presbyterian Hosptial. What happens when two great medical schools bring their highly regarded faculties and groundbreaking research to one hospital? You get more innovation. A wider breadth of expertise. Greater diversity. And most importantly, better outcomes for patients. The physician faculties of Columbia and Weill Cornell have powered NewYork-Presbyterian to U.S. News & World Reportâ&#x20AC;&#x2122;s top ranking for New York hospitals for 17 straight years.

Learn more at nyp.org/amazingadvances

PROGRAM COORDINATOR RECOGNITION AWARD Recipients: Silviya H. M. Eaton, MBA, MA, C-TAGME, Boston, MA

Frances Clark, BS, C-TAGME, Dayton, OH

PROGRAM DIRECTOR RECOGNITION AWARD Recipients: Lyell K. Jones, Jr, MD, FAAN, Rochester, MN

Raymond Price, MD, Philadelphia, PA

CAREER DEVELOPMENT AWARD Funded by the American Academy of Neurology.

Recipient: Aasef Shaikh, PhD, MD, Case Western Reserve University

CLINICAL RESEARCH TRAINING SCHOLARSHIP (FORMERLY FELLOWSHIP) Funded by the American Academy of Neurology.

Recipients: Christopher Benjamin, PhD, Yale New Haven Medical Center

Matthew Bevers, PhD, MD, Brigham Women’s Hospital/Harvard University

Peter Kang, MD, Washington University

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN ALS

Funded by the American Brain Foundation and the ALS Association.

Recipient: Peter Creigh, MD, University of Rochester

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN DEMENTIA WITH LEWY BODIES

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN MULTIPLE SCLEROSIS Supported by Genzyme and the American Academy of Neurology.

Recipient: Giulia Fadda, MD, University of Pennsylvania

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN MUSCULAR DYSTROPHY

Funded by the American Brain Foundation and the Muscular Dystrophy Association.

Recipient: Katharine Nicholson, MD, Massachusetts General Hospital, Brigham, Harvard

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN NEUROMUSCULAR DISEASE

Funded by the American Brain Foundation, and the Muscle Study Group.

Recipient: Davut Pehlivan, MD, Baylor College of Medicine

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN PARKINSON’S DISEASE Supported by Lundbeck in collaboration with the American Academy of Neurrology.

Recipient: Krithi Irmady, MD, PhD, Rockefeller University

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN TOURETTE SYNDROME Funded by the American Brain Foundation and the Tourette Association of America.

Recipient: Wissam Georges Deeb, MD, University of Florida College of Medicine

NEUROSCIENCE RESEARCH TRAINING SCHOLARSHIP

Funded by the American Academy of Neurology.

Recipients: Marianna Spatola, MD, Ragon Institute of MGH, MIT, and Harvard

Funded by the American Brain Foundation, and The Mary E. Groff Charitable Trust.

Brett McCray, MD, PhD, Johns Hopkins University

Recipient: Bhavana Patel, MD, University of Florida College of Medicine

Andrew Findlay, MD, Washington University

PRACTICE RESEARCH TRAINING SCHOLARSHIP (FORMERLY FELLOWSHIP) Funded by the American Academy of Neurology.

Recipient: Archana Patel, MD, Children’s Hospital Boston

Saturday, April 21, 2018 • AANextra

SUSAN S. SPENCER CLINICAL RESEARCH TRAINING SCHOLARSHIP (FORMERLY FELLOWSHIP)

Funded by the American Brain Foundation, the American Epilepsy Society, and the Epilepsy Foundation.

Recipient: Hiroki Nariai, MD, UCLA Medical Center

CLINICIAN SCIENTIST DEVELOPMENT AWARD IN INTERVENTIONAL NEUROLOGY

Funded the American Brain Foundation and the Society of Vascular and Interventional Neurology.

Recipient: Sunil A. Sheth, MD, McGovern Medical School at The University of Texas Health Science Center

MCKNIGHT CLINICAL TRANSLATIONAL RESEARCH SCHOLARSHIP IN COGNITIVE AGING AND AGE-RELATED MEMORY LOSS Funded by the McKnight Brain Research Foundation through the American Brain Foundation, and the American Academy of Neurology.

Recipients: Brice McConnell, PhD, MD, University of Colorado Denver School of Medicine

Kimberly Albert, PhD, Vanderbilt University Medical Center

SAFETY AND QUALITY AWARD

Sponsored by the American Academy of Neurology.

Recipients: Lily Grossmann, MD, Boston, MA

Yi Li, MD, PhD, Worcester, MA

Michael Robers, MD, Phoenix, AZ

Mauricio Villamar, MD, Lexington, KY

IRWIN SCHATZ AWARD FOR AUTONOMIC DISORDERS

Sponsored by the American Academy of Neurology and endowed by Lundbeck, Inc.

Recipient: David S. Goldstein, MD, PhD

BRUCE S. SCHOENBERG INTERNATIONAL AWARD IN NEUROEPIDEMIOLOGY Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.

Recipient: Fred Sarfo, MD, PhD

Congratulations 2018 Neuro Film Festival Winners!

SLEEP SCIENCE AWARD

Sponsored by the American Academy of Neurology and the American Academy of Neurology Sleep Section and endowed by Cephalon, Inc.

Recipient: Bradley F. Boeve, MD

JON STOLK AWARD IN MOVEMENT DISORDERS FOR YOUNG INVESTIGATORS Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma.

Recipient: Nandakumar Narayanan, MD, PhD

Moving and inspirational videos were submitted by people of all ages for this year’s Neuro Film Festival®. Each told its own powerful story that built a strong case for why more funding is needed for research to cure brain disease. Congratulations to this year’s winners: GRAND PRIZE WINNER

Neuroscience Is…™ Cool

(category kids ages 13-17)

Anjali Sadarangani for Neuroscience Is Cool!

H. RICHARD TYLER AWARD

Sponsored by the American Academy of Neurology and the American Academy of Neurology History Section

There is energy all around us, but the brain is what makes it all perceivable. This video explores the brain’s role in processing the sights and sounds that we experience every day.

Recipient: Andrew J. Solomon, MD, Burlington, VT

KENNETH M. VISTE JR., MD, PATIENT ADVOCATE OF THE YEAR AWARD

Neuroscience Is…™ Rewarding

Sponsored by the American Academy of Neurology and endowed by gifts from Dr. Viste’s colleagues, friends and patients.

(category for undergraduate and graduate students, medical students, and residents)

Recipient: Oleg Chernyshev, MD, PhD

ROBERT WARTENBERG LECTURE Recipient: Lisa M. DeAngelis, MD, FAAN Memorial Sloan-Kettering Cancer Center, New York, NY

HAROLD WOLFF-JOHN GRAHAM AWARD: AN AWARD FOR HEADACHE/FACIAL PAIN RESEARCH Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals.

Alison Caldwell for Why I Love Neuroscience. Alison wanted to be an astronaut ever since she was a little kid. But in college she discovered neuroscience. She was amazed to learn there are more synaptic connections in the brain than there are stars in the Milky Way Galaxy. Today, she is pursuing her PhD in neuroscience. GRAND PRIZE WINNER

Neuroscience Is…™ Essential (category for patients, families, and caregivers)

Recipient: William R. Renthal, MD, PhD

GRAND PRIZE WINNER



Trish Flanagan for Morgan’s Story. Morgan was born with an HNRNPH2 mutation. The condition inhibits her normal development, but it cannot limit the spirit of love and happiness that surrounds her everywhere she goes.

GRAND PRIZE WINNER

Neuroscience Is…™ Critical

(category for advocates, patient groups, and neurology professionals) Carlos Muniz for Tough as Iron. A group of doctors traveled to a small town in the Dominican Republic to visit residents affected by pantothenate kinase-associated neurodegeneration (PKAN), a rare neurologic condition that causes involuntary movements. You can view the winning videos, as well as all of this year’s, submissions on the Neuro Film Festival YouTube channel at Youtube.com/user/NeuroFilmFest/playlists . 

Celebrating 40 years as a pioneer in neuroscience.

At Biogen, we are committed to making a difference in the lives of patients with neurological and neurodegenerative conditions. Thatâ&#x20AC;&#x2122;s why we have spent four decades developing and delivering meaningful therapies for patients worldwide.

Visit us at Biogen.com

to learn more.

03/18 FCH-US-3489